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  Abbreviations	  
	  
ACS:	   	   Acute	  Coronary	  Syndrome(s)	  
ACE-­‐I:	   	  	   Angiotensin	  Converting	  Enzyme	  
AF:	   	  	   Atrial	  Fibrillation	  
AHF:	   	  	   Acute	  Heart	  Failure	  
AHT:	  	   	  	   Arterial	  Hypertension	  	  
AMI:	  	   	  	   Acute	  Myocardial	  Infarction	  
ARA:	   	  	   Aldosterone	  Receptor	  Antagonist	  
ARB:	  	   	  	   Angiotensin	  II	  Receptor	  Blocker	  	  
BP	  (SBP):	   Systolic	  Blood	  Pressure	  
bpm:	   	  	   beats	  per	  minute	  
CAD:	   	  	   Coronary	  Artery	  Disease	  
CI:	   	  	   Confidence	  Interval	  
CKD-­‐EPI:	  	   Chronic	  Kidney	  Disease	  Epidemiology	  Collaboration	  
CFR:	   	  	   Case	  Fatality	  Rate	  
CPR:	   	  	   Cardio	  Pulmonary	  Resuscitation	  
COPD:	   	  	   Chronic	  Obstructive	  Pulmonary	  Disease	  
CVD:	   	  	   CardioVascular	  Disease	  
DM:	   	  	   Diabetes	  Mellitus	  
DTB:	   	  	   Door-­‐To-­‐Balloon	  time	  
ECMO:	   	  	   Extra	  Corporeal	  Membrane	  Oxygenation	  
eGFR:	   	  	   estimated	  Glomerular	  Filtration	  Rate	  
FU:	   	  	   Follow-­‐Up	  
h:	   	  	   hour	  
HF:	   	  	   Heart	  Failure	  
HF-­‐PEF:	   	  	   Heart	  Failure	  with	  Preserved	  Ejection	  Fraction	  
HF-­‐REF:	   	  	   Heart	  Failure	  with	  Reduced	  Ejection	  Fraction	  
	  HR:	   	  	   Heart	  Rate	  
HR:	   	  	   Hazard	  Ratio	  
IABP:	   	  	   Intra-­‐Aortic	  Balloon	  Pump	  
IQR:	   	  	   Inter	  Quartile	  Range	  
IV:	   	  	   IntraVenous	  
kg:	   	  	   kilogram	  
LBBB:	   	  	   Left	  Bundle	  Branch	  Block	  
LVAD:	   	  	   Left	  Ventricular	  Assist	  Device	  
LVEDD:	   	  	   Left	  Ventricular	  End	  Diastolic	  Diameter	  
LVEF:	   	  	   Left	  Ventricular	  Ejection	  Fraction	  
min:	   	  	   minute	  
MR:	   	  	   Mitral	  Regurgitation	  
NIV:	   	  	   Non-­‐Invasive	  Ventilation	  
NSTE-­‐ACS:	  	   Non	  ST-­‐segment	  Elevation	  Acute	  Coronary	  Syndrome	  
NSTEMI:	  	  	   Non	  ST-­‐segment	  Elevation	  Myocardial	  Infarction	  
NYHA:	   	  	   New	  York	  Heart	  Association	  
OR:	   	  	   Odds	  Ratio	  
PAD:	   	  	   Peripheral	  Artery	  Disease	  
pPCI:	   	  	   primary	  Percutaneous	  Coronary	  Intervention	  
PPCM:	   	  	   Peripartum	  Cardiomyopathy	  
RD:	   	  	   Renal	  Dysfunction	  
ROC:	   	  	   Receiver	  Operating	  Characteristic	  
SBP:	   	  	   Systolic	  Blood	  Pressure	  
SD:	   	  	   Standard	  Deviation	  
STEMI:	   	  	   ST-­‐segment	  Elevation	  Myocardial	  Infarction	  
TIMI	  :	   	  	   Thrombolysis	  In	  Myocardial	  Infarction	  
UA	   	  	   Unstable	  angina	  
VKA:	   	  	   Vitamin	  K	  Antagonist	  
Y:	   	  	   year	  




I.1	  Cardiac	  disease	  in	  women	  
Cardiovascular disease (CVD: coronary artery disease [CAD], stroke and other 
CVD) is the leading killer of women at all ages. According to the latest European 
CVD statistics (2012) it accounts for 52% of the causes of death in European women 
(vs. 42% in men). (Figure	  1)	  	  
	  




The longstanding disbelief that CAD does not occur in younger women was 
once again refuted by these statistics that point out CAD as the primary cause of 
death in 10% of the women <65 year of age in Europe (vs. 12% in men). (Figure	  2)	  1	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Figure	  2	  	   Deaths	  under	  65	  by	  cause,	  women,	  Europe	  1	  
	  
 
CVD is also the leading cause of non-obstetric mortality during pregnancy 
while the number of women with pre-existing CVD or the development of cardiac 
problems during pregnancy is increasing and there is a lack of evidence-based data 
on the treatment of these patients. 2-5 
The interest for the female patient and gender differences in cardiac disease 
substantially increased during the last two decades 6, 7, reflecting the need for more 
gender specific knowledge in order to reach better heart health care for women.  
More recently, strategies to improve the outcome of CVD in women were proposed 
during several international scientific symposia at both sides of the Atlantic. 8-10 
Among these strategies was the encouragement of cardiovascular research in women 
with attention for gender-specific analysis and higher enrolment of women in clinical 
trials. There are many reasons why gender-specific basic and clinical research is 
valuable in cardiac disease: first there is the anatomical difference: a woman’s heart is 
smaller and has a smaller vascular bed 11, 12, second there are important gender 
differences in the pathophysiology of CVD  13-17, the impact of cardiovascular risk 
factors  18-20 and the effects of pharmacological therapy  21-23, third women tend to have 
more co-morbidities, especially at older age, fourth symptoms in women may be 
different 24-26 and sometimes misleading with the risk of under-recognition 27 and 
treatment-delay. Finally woman-specific cardiac disease exists such as pregnancy 
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related cardiac disease while Tako-Tsubo syndrome 28 and toxic cardiomyopathy 
following chemotherapy for breast cancer occur predominantly in women. 29  
Research on gender differences in cardiac disease initially focused on coronary 
heart disease but expanded to the different fields of cardiology including prevention 
30, hypertension, heart failure (HF) 31-38, arrhythmia 39-41, valvular heart disease 42, 43 and 
complications of interventional cardiology. 44, 45  
This thesis focuses on gender differences in acute cardiology. Acute Coronary 
Syndromes (ACS) and Acute Heart Failure (AHF) are the major reasons for urgent 
hospital admission in this setting. Both are associated with high morbidity and 
mortality and require immediate risk stratification and initiation of evidence based 
and guideline recommended treatment strategies.  
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I.2	  Acute	  Coronary	  Syndromes	  in	  women	  
‘Acute Coronary Syndromes’ (ACS) comprise unstable angina (UA), non ST-
segment elevation myocardial infarction (NSTEMI) and ST-segment elevation 
myocardial infarction (STEMI). UA/NSTEMI and STEMI have a different clinical 
presentation but share a common pathophysiological substrate: atherosclerotic 
plaque rupture or erosion with different degrees of concomitant thrombosis. 46  
The INTERHEART study identified 9 modifiable risk factors associated with 
the risk for an ACS. These were the same for men and women: smoking, abnormal 
lipids, hypertension, diabetes, abdominal obesity and psychosocial stress were 
associated with increased risk while a healthy diet, moderate alcohol consumption 
and physical activity had a protective effect against myocardial infarction. 19 There are 
some gender differences in the impact and incidence of a risk factor: hypertension, 
diabetes, physical inactivity, lack of moderate alcohol intake and smoking (especially 
at young age) are more powerful risk factors in women. 18-20 Hypertension and 
diabetes are more prevalent among women with ACS while smoking is encountered 
more in men with ACS.  
Women experience their first myocardial infarction on average 10 years later 
than men. Possible explanations for the later presentation in women are the 
protective effect of endogenous oestrogen before menopause and the higher risk 
factor burden in men at younger age. 47 In contrast, women who do develop an ACS 
at younger age often have a higher risk factor burden than men. 48 
Atherosclerotic lesions typically form over the course of years but the 
thrombotic complications that cause ACS occur suddenly. An occlusive thrombus 
arrests flow and causes STEMI while non-ST elevation ACS (NSTE-ACS) results from 
an incomplete or transient obstructive flow at the site of a critical stenosis. Rupture of 
the fibrous cap of a plaque causes most of the ACS. Plaque rupture is more often 
associated with thrombus formation in women as in men. 49 Plaque erosion through 
the intima of a calcified nodule triggers a small amount of ACS; autopsy studies 
demonstrated that this is encountered more in young female smokers. 14, 50 
Spontaneous coronary artery dissection is another but very rare cause of ACS, 
occurring more in young women and often after emotional or physical stress. 51 About 
one third of spontaneous coronary artery dissections occur during or early after 
pregnancy, the true underlying mechanism is not clear but it is believed that 
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hormonal changes, haemodynamic stress and changes in auto-immune status play a 
role. 52 
An ACS is often the first presentation of CAD in men while angina 
predominates as the onset of CAD in women. 53 Within the ACS spectrum, women 
present more with UA/NSTEMI 13, 54-56 and exhibit fewer high-risk angiographic 
features on coronary angiography; 10-30% of women with ACS present without 
major coronary stenosis compared to 3-15% of the men. 56, 57 However, as demonstrated 
by the WISE investigators, non-obstructive CAD is also associated with adverse 
outcomes over the longer term among women with signs and symptoms of 
ischaemia and should be treated appropriately. 58, 59  
The diagnosis, risk stratification and management of ACS are based on:  
1. Symptoms  
“Chest pain, often described as a pressure or heaviness, often radiating to the left arm, 
neck or jaw, occurring at rest or with minimal exertion. This may be intermittent 
(>NSTE-ACS) or persistent (>STEMI) and can be accompanied by other symptoms such 
as diaphoresis, nausea and dyspnoea”  
There is on-going debate on gender differences in symptoms of ACS but the most 
important finding is that chest pain is the predominant symptom in both men and 
women but the absence of chest pain is more prevalent in women. However the 
majority of women without chest pain report at least 1 non-chest pain symptom, with 
more non-chest pain symptoms in women vs. men (back- neck or jaw pain, nausea 
and vomiting, shortness of breath, palpitations, dizziness, fatigue, …). Gender 
differences in the absence of chest pain are more pronounced among younger 
patients and become attenuated with age. 25, 26 The absence of chest pain or the atypical 
character of chest pain can lead to a delay in diagnosis and treatment. 
2.  ECG changes  
“No, new or presumed new significant ST segment-T wave changes or new left bundle 
branch block” 
There are little data regarding gender differences in ECG in the setting of an ACS. 
For the diagnosis of STEMI: an ST-segment elevation at the J point should be present 
in 2 contiguous leads and be ≥0,25mV in men <40 years and ≥ 0,2mV in men over the 
age of 40. In women ST-elevation should be ≥0,15 in leads V2-3 and/or 0,1mV in 
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other leads. 60 In a mixed group of STEMI and NSTEMI patients, female gender was 
associated with lateral ST-depression, higher heart rate and longer QTc-interval 
whereas men had a longer QRS duration and a higher voltage of the QRS complex. 
Post MI ST-segment elevation in the anterior leads was associated with worse 
outcome in women while ST-depression in the lateral leads was associated with 
worse outcome in men in the same study population. 61 
 
3. The detection of cardiac bio-markers :  
“Detection of a significant rise and/or fall in cardiac biomarkers (preferably cardiac 
troponin) with at least one value above the 99th percentile upper reference limit is 
necessary for the diagnosis of myocardial infarction”  
Gender differences in the 99th percentile reference limit have been demonstrated 
for the old as well as for the new high sensitive troponin assays with higher 99th 
percentiles for males. 62, 63 For the moment male thresholds are used in clinical 
practice for both genders.  
Men have higher attack rates of myocardial infarction. Overall, attack rates of 
STEMI declined in both men and women over the last 25 years but these declines 
were less pronounced among women. Despite the observed decline in case fatality 
rates for both sexes, women remained at higher risk for mortality and complications. 
64-67 Local data from the Ghent Monica Registry (1983-2008) confirm the decline in 
attack rates, which is less pronounced in women than in men. During the same 
period a decline in 28-day case fatality rate is observed in Ghent, in both men and 
women (Unpublished data courtesy prof. dr. Koen Van Herck, Figure	  3). Women 
however remain at higher risk but the gap is narrowing. (Unpublished data, courtesy 
prof. dr. Koen Van Herck, Figure	  4) 
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Figure	  3	  	   Evolution	  of	  attack	  rates*/10.000	  men	  and	  women,	  aged	  25-­‐69	  	  
MONICA	  Registry	  Ghent	  ,	  1983-­‐2008	  
	  Figure	  4	   Evolution	  of	  in-­‐hospital	  case	  fatality	  rates	  in	  men	  and	  women,	  aged	  25-­‐69	  
Monica	  Registry	  Ghent,	  1983-­‐2008	  	  
	  
	   	   	   CFR=	  case	  fatality	  rate	  
	  
In the current guidelines on ST-segment elevation ACS and non ST-segment 
elevation ACS (NSTE-ACS) women are considered as ‘a special patient’ subset with 
the recommendation to treat both genders in a similar fashion (class I 
recommendation, level B in NSTE-ACS and level C in STEMI) and to dose 
antithrombotic therapies with close attention to bleeding risk. 60, 68  
Important advances in the acute treatment of STEMI have been made during 
the last three decades; in the eighties acute reperfusion with fibrinolytic agents was 
introduced followed by trials in the nineties that demonstrated the superiority of 
primary percutaneous intervention (pPCI) in opening the infarct related artery. 69 
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Nowadays pPCI is the treatment of choice for STEMI, this treatment proved benefit 
in women and men as compared to thrombolytic therapy 70-73 and is increasingly used 
in Europe and Belgium. 74, 75 Further advances in the treatment of ACS include 
additional treatments such as beta-blocking agents, dual antiplatelet therapy, high 
dose statins and angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin II 
receptor blockers (ARB). 
Women constitute approximately one fourth of the patients admitted with 
STEMI. Different analyses demonstrated a worse short-term prognosis for women 
suffering a myocardial infarction 76, especially those below 60 years-of-age. 77, 78 The 
introduction of more sensitive assays for the diagnosis of ACS-subtypes, allowed to 
evaluate the outcomes per ACS-subtype: an analysis of Berger et al. showed that 
women with STEMI have a higher adjusted risk for 30 day mortality whereas this 
mortality risk was lower in women with UA and NSTEMI as compared to men. 56 
Champney et al. demonstrated a worse outcome for younger women, irrespective of 
ACS type, while older women showed no mortality differences (in STEMI) or even a 
better survival (in NSTEMI). 79 Therefore, intensive research has been performed on 
the reasons behind the differences in short term outcome after STEMI; in general 
women present with less chest pain or other ‘atypical’ symptoms 25, 26, a worse risk 
profile 80 and are less likely to receive guideline based therapies 81 or to undergo 
coronary interventions. 82, 83 Furthermore women suffer more complications after 
percutaneous interventions. 84, 85 Recent reports demonstrate that the gender gap in 
access to early intervention is closing. 81, 86 In contrast men are at higher risk of 
malignant ventricular arrhythmia and sudden death in the pre-hospital phase 87, 
probably due to a higher parasympathetic autonomic tone in women which is 
thought to protect them against ventricular fibrillation. 88 
An overview of the main gender-differences and knowledge gaps in ACS is 
summarised in Table	  1.
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Table	  1	  	  Women	  vs.	  Men	  in	  ACS	  
Age	   Older,	  on	  average	  10	  years	  	  
Risk	  factors	   More	  hypertension	  and	  more	  diabetes	  
Less	  smoking	  
Protective	  effect	  of	  oestrogen	  before	  menopause	  
Higher	  burden	  of	  risk	  factors	  at	  younger	  age	  
Pathophysiology	   Young	  and	  smoking:	  higher	  incidence	  of	  plaque	  erosion	  
More	  thrombus	  formation	  in	  case	  of	  plaque	  rupture	  
More	  coronary	  artery	  dissection	  (rare)	  
Micro-­‐vascular	  dysfunction,	  endothelial	  dysfunction	  	  
Co-­‐morbidity	   More:	  diabetes,	  hypertension,	  depression	  
Type	   More	  NSTE-­‐ACS,	  less	  STEMI	  
ECG	   Lateral	  ST-­‐depression,	  higher	  heart	  rate	  and	  longer	  QTc	  
Biomarkers	   Lower	  99th	  percentile	  upper	  reference	  limit	  
Anatomical	   Less	  obstructive	  CAD,	  less	  atherosclerotic	  burden	  	  
Symptoms	   Higher	  proportion:	  no	  chest	  pain	  
More	  non-­‐chest	  pain	  symptoms	  
Treatment	   Delayed	  (patient	  and	  system	  related)	  
Less	  invasive	  
Complications	   More	  bleeding,	  vascular	  complications	  
More	  contrast	  induced	  AKI	  
Outcome	   Pre	  hospital	  phase:	  less	  sudden	  death	  
NSTE-­‐ACS:	  better	  outcome	  	  
STEMI:	  worse	  outcome	  in	  young	  women	  
Knowledge	  gaps	   • Reason	  for	  higher	  mortality	  in	  younger	  women	  with	  STEMI	  	  
• Determinants	  for	  treatment	  delay	  in	  women	  
• Best	  approach	  to	  assess	  chest	  pain	  and	  non	  chest	  pain	  
symptoms	  suggestive	  of	  CAD	  in	  women	  
• Sex	  differences	  in	  ECG	  in	  ACS	  
• Could	  the	  use	  of	  sex-­‐specific	  cut	  off	  values	  for	  troponin	  
improve	  diagnosis?	  	  
ACS=	  acute	  coronary	  syndromes,	  NSTE-­‐ACS:	  non	  ST	  segment	  elevation	  ACS,	  	  
STEMI:	  ST-­‐segment	  	  elevation	  myocardial	  infarction,	  CAD:	  coronary	  artery	  disease,	  AKI=	  acute	  kidney	  
injury	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I.3	  Acute	  Heart	  Failure	  in	  women	  
Heart failure (HF) is defined as the clinical syndrome that develops as a 
consequence of an abnormality of the heart with typical symptoms (e.g. 
breathlessness and fatigue) and clinical signs (e.g. peripheral oedema). Any 
abnormality of the heart can cause HF (structural: e.g. valvular heart disease, 
electrical: e.g. atrial fibrillation [AF], mechanical: e.g. systolic dysfunction). Left 
ventricular dysfunction caused by myocardial infarction or CAD is the commonest 
cause of HF in the Western world and is more prevalent among men. HF with 
preserved ejection fraction (HF-PEF) is more prevalent among women. 36  
The prevalence of chronic HF increases with age for both men and women 
with more women than men having HF after 79 years-of-age. 89 In general women 
with chronic HF have an improved survival as compared to men, despite the fact that 
they receive less evidence-based therapies for HF. The reason behind this better 
survival is not completely understood at this moment. 36 
The syndrome of AHF is defined as the rapid onset, or deterioration of the 
aforementioned symptoms and signs resulting in the need for urgent therapy. 90 
Patients with AHF present with different clinical pictures ranging from a condition 
characterised by a gradual increase in peripheral oedema and dyspnoea due to fluid 
retention called ‘acute decompensated heart failure’ to the most severe form of AHF 
characterised by hypo-perfusion and tissue hypoxia called ‘cardiogenic shock’. 91  
The commonest form of AHF is decompensated pre-existing chronic HF, often 
triggered by a precipitating factor such as infection, arrhythmia (especially AF), 
problems with compliance, renal dysfunction and many more. In the setting of ACS, 
AHF occurs in 20-30% of the cases and represents the most important cause of 
cardiogenic shock. Despite the fact that women show greater myocardial salvage 
after pPCI 92 and are believed to be protected against apoptosis and cell death 93 they 
are at higher risk for the development of HF during hospitalisation for ACS. 94 
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Tako-Tsubo cardiomyopathy is an uncommon type of AHF that occurs 
predominantly in postmenopausal women after emotional and/or physical stress. 28 It 
can mimic a STEMI and is characterised by a transient and severe left ventricular 
dysfunction in the absence of significant CAD. Several possible mechanisms such as 
multi-vessel coronary artery spasm, micro-vascular dysfunction, myocarditis and 
catecholamine toxicity have been proposed but its pathophysiology remains not well 
understood. 95 
Peripartum cardiomyopathy (PPCM) is directly related to pregnancy and is 
defined as the development of HF during the last month of pregnancy or the months 
following pregnancy without any other identifiable cause of HF. 96 Women with 
PPCM usually present with typical signs and symptoms of HF. When PPCM occurs 
during pregnancy many of these symptoms are similar to those of normal pregnancy 
and the diagnosis is often delayed. 97 As a consequence many women with PPCM 
present in a later stage with de novo AHF requiring emergency admission and 
intensive cardiac care. The treatment is mainly supportive; when medical therapy is 
not sufficient mechanical support may be necessary. 98 
The prevalence of co-morbidities is high in patients with AHF: these can be of 
cardiac (CAD, arrhythmia [especially AF], valvular heart disease) and non-cardiac 
origin (hypertension, chronic kidney disease, chronic obstructive pulmonary disease 
[COPD], diabetes, peripheral vascular disease, anaemia…). 99 Both HF and AF are 
considered as the two epidemics of modern cardiovascular medicine. 100 These 
conditions may interact: a rapid ventricular rate can trigger AHF, and HF increases 
atrial stretch, which can make AF more resistant to therapy. The incidence of AF 
increases when HF severity worsens and AF is associated with worse outcome in HF 
patients. 101 
Due to improved survival after ACS and an ageing population, AHF has 
become the leading cause for urgent hospital admission in the population above 65 
years-of-age. 102, 103 AHF is associated with increased mortality during and after 
discharge and a high risk (up to 30%) of hospital readmission making it a major 
public health challenge. 104-106
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Registry data show that women comprise half of the patients hospitalised for 
AHF but proportions of women in randomised controlled trials in this setting are far 
below 50%, illustrating that women are underrepresented in these trials. 38  
  On average women with AHF are 5 years older (mean age women: 73.1 
years, men: 67.8 years in the Euro Heart Failure Survey II), have other co-morbidities 
and present more with HF-PEF 32, 33 Ischaemic heart disease, COPD and peripheral 
artery disease occur more in men with AHF while hypertension, diabetes and 
chronic kidney disease occur more in women with AHF. Some AHF registries 
demonstrated small but non-consistent sex-differences in the prevalence of AF. 31-33, 35, 37 
Despite differences in age, comorbidities, aetiology and management most 
AHF registries found no gender differences in short-term outcome while a Danish 
group demonstrated a better adjusted long-term survival for women in patients 
hospitalised with congestive HF. 31-33, 37, 107, 108  
An overview of the main gender-differences and knowledge gaps in AHF is 
summarised in Table	  2.
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Table	  2	  	  Women	  vs.	  men	  in	  AHF	  
Age	   Older,	  on	  average	  5	 years	  
Pathophysiology	   More	  HF-­‐PEF	  
Less	  ischaemic	  aetiology	  
Higher	  proportion	  of	  HF	  complicating	  MI	  
Tako	  Tsubo	  more	  prevalent	  among	  postmenopausal	  women	  
Female	  specific:	  Peripartum	  cardiomyopathy	  
Co-­‐morbidity	   Less:	  COPD,	  peripheral	  artery	  disease,	  CAD	  
More:	  	  hypertension,	  diabetes,	  chronic	  kidney	  disease	  
Atrial	  Fibrillation?	  	  
Treatment	   No	  significant	  differences	  in	  current	  registries	  
Prognosis	   No	  significant	  differences	  in	  short-­‐term	  outcome.	  	  
Better	  long-­‐term	  outcome.	  
Knowledge	  gaps	   • Why	  do	  women	  develop	  more	  HF	  in	  the	  setting	  of	  
ACS?	  
• Have	  HF	  treatments	  the	  same	  effect	  in	  women	  or	  
should	  we	  treat	  them	  differently?	  
• Why	  is	  the	  long-­‐term	  survival	  better	  in	  women?	  
AHF=	  acute	  heart	  failure,	  HF-­‐PEF=	  heart	  failure	  with	  preserved	  ejection	  fraction,	  HF=	  heart	  
failure,	  MI=	  myocardial	  infarction,	  COPD=chronic	  obstructive	  pulmonary	  disease,	  	  	  	  	  	  
CAD=coronary	  artery	  disease,	  ACS=	  acute	  coronary	  syndrome	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II.	  Aims	  and	  outline	  of	  the	  thesis	  
________________________________________________________	  
The general aim of this thesis is to gain further insight into the clinical 
characteristics and outcomes of women with acute cardiac disease, more specifically 
STEMI and AHF. 
Aims	  A-­‐B-­‐C	  
When starting this project the central question was: ‘Are female patients 
presenting with acute cardiac disease equal or different to male patients in terms of 
prognosis’?  
Aim	  A	  
The last 2 decades many investigators reported a worse outcome for women vs. 
men with STEMI. 54, 109, 110 Higher age, more advanced disease, the presence of 
comorbidity (especially hypertension and diabetes), longer ischaemic times (patient 
and system related), a worse clinical condition on presentation, the underuse of 
evidence-based therapy and invasive reperfusion strategies and a higher pre-hospital 
mortality for men were pointed out as confounding factors. 83, 109 Primary angioplasty is 
the treatment of choice in STEMI but there is conflicting evidence regarding gender-
based differences in the short-term outcome after pPCI. 73, 111-118 
The Thrombolysis In Myocardial Infarction (TIMI) risk score for STEMI is a 
simple arithmetic score that predicts short-term mortality based on age and clinical 
data on admission, female gender is not included in this score. 119 There are no data on 
the predictive performance of the TIMI risk score for STEMI when applied to a 
community based cohort of men and women in the current era of pPCI, stenting and 
adjunctive antiplatelet therapy. 
Aim	  A: To compare in-hospital mortality rate and the predictive performance of 
the TIMI risk score between male and female Belgian STEMI patients 
undergoing pPCI.  
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Aim	  B	  
Chronic kidney disease, even mild, is independently associated with in-hospital 
mortality in STEMI patients treated with pPCI. 120, 121 Data on gender differences in 
prevalence of renal dysfunction at admission in pPCI treated STEMI patients are 
scarce and have seldom been accounted for when evaluating gender differences in 
outcome, furthermore different definitions (serum creatinine levels vs. estimated 
Glomerular Filtration Rate [eGFR] values) and different methods of estimating 
creatinine clearance have been applied. 112, 118, 122, 123 It is assumed that the newer Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation leads to a smaller 
average bias in a clinical population with a wide range of GFRs. 124 
	  Aim	  B: To investigate gender differences in prevalence and prognostic impact of 
renal dysfunction at admission (assessed by the CKD-EPI equation) on in-
hospital mortality in STEMI patients undergoing pPCI.  
Aim	  C	  
The proportion of patients hospitalised with pre-existing AF and HF is 
increasing. 125, 126 There are little data regarding gender differences in treatment and 
prognostic impact of AF in AHF patients.  
Aim	  C: To evaluate gender differences in the incidence, treatment and outcome of 
co-occurring AF in AHF.  
	  
Accordingly we compared in-hospital mortality and the predictive 
performance of the TIMI risk score in STEMI between male and female patients 
undergoing pPCI and we evaluated gender differences in the setting of STEMI and 
AHF while focusing on the incidence and impact on prognosis of selected clinical 
variables (renal dysfunction in STEMI and AF in AHF).	  (Aims	  A-­‐B-­‐C:	  chapters	  1-­‐2-­‐3)
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Aims	  D-­‐E	  
Women who are confronted with acute cardiac disease at a younger age 
present a major challenge. 
Many authors have demonstrated a worse outcome for women with STEMI at 
younger age. 77, 78 This was not yet reported among younger women admitted with 
AHF.  
Aim	  D: To evaluate gender differences among younger men and women 
undergoing pPCI for STEMI (<65 years-of-age) or admitted with AHF and co-
occurring AF (<75 years-of-age).  
	  
We further evaluated the aforementioned gender differences of aims A and C 
in two age groups, a younger and older age group (< and ≥ 65 years in STEMI, < and 
≥ 75 years in AHF complicated with AF).	  (Aim	  D:	  chapter	  1	  and	  3)	  
 
Finally the number of pregnant women with pre-existing CVD or the 
development of cardiac problems such as PPCM during pregnancy is increasing. 4 
Despite the low incidence of PPCM and potential reversibility or stabilisation with 
current medical therapy, some patients may evolve to severe haemodynamic 
compromise and death. 127 There are limited data on the use of mechanical support in 
PPCM patients.  
Aim	  E: To evaluate the feasibility, efficacy and safety of mechanical support in 
patients with PPCM.  
Finally we evaluated the feasibility, efficacy and safety of mechanical support 
in critically ill patients presenting with PPCM refractory to medical supportive 
therapy. (Aim	  E:	  chapter	  4) 
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III.	   Patients	  and	  methods	  
_______________________________________________________	  
	  
The research aims were explored in existing datasets, reflecting real world 
practice in unselected patients. These databases represent Belgian hospitals of 
various sizes and provide recent data regarding management of STEMI and AHF.  
	  
III.1	  STEMI	  patients	  
Dataset	  
The Belgian STEMI registry is a prospective observational registry of unselected 
Belgian STEMI patients admitted in 113 hospitals and registered by 72 Belgian 
hospitals. 128 (Figure	  5) The objective of this prospective registry is to collect real-life 
data on the clinical characteristics, the management and the in-hospital outcome of 
Belgian STEMI patients. The registry started in 2007 and contains demographics, 
previous history, clinical characteristics at admission, infarct localisation, practice 
patterns and in-hospital outcomes. The registry is an initiative of the Belgian 
Interdisciplinary Working Group on Acute Cardiology (BIWAC) and is supported by 
the Belgian government of Social Affairs and Public Health and the Belgian College 
of Cardiologists. All Belgian cardiologists working in hospitals with acute care 
facilities are required to prospectively collect data on all admitted STEMI patients 
starting from January 2007.  
During the period January 2007-February 2011, a total of 9,535 STEMI patients 
were registered in the database. Out of these, all patients treated with pPCI <24 
hours after hospital admission were selected (8,073 patients) to compare in-hospital 
mortality rate and predictive performance of the TIMI risk score between men and 
women. (AimA)	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For Aim	  B we retrospectively collected admission values of serum creatinine of 
patients (N= 1,751) admitted in eight out of 28 tertiary care centres participating in 
the STEMI registry. Of these 1,638 patients, treated with pPCI <24 hours after 
hospital admission, were selected and included in the analysis. The eGFR was 
calculated using the CKD-EPI equation based on the admission value of serum 
creatinine. 124 The eGFR could not be calculated in 11.9% of the cases due to missing 
values.  
The Belgian STEMI database was registered with clinicaltrials.gov 
(NCT00727623). 128 The study was approved by the central ethical committee of the 
Ghent University Hospital (2011/455). A yearly audit, conducted by an external 
commission, of 10% of all patients’ files was performed to verify the validity of the 
data; 84% of the data were retrieved in the source documents and there was a 96% 
concordance rate between source documents and case report forms.  
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Aim	  A-­‐D:	  A multivariable logistic regression model was created to evaluate the 
relationship between gender and in-hospital mortality, including all TIMI risk score 
variables (age group (< and ≥ 65 years old), history of hypertension, history of 
diabetes, previous CAD, Killip Class >I, ischaemic time >4 hours, admission systolic 
blood pressure (SBP) <100mmHg, admission heart rate >100 beats per minute (bpm), 
weight <67 kg, anterior myocardial infarction or LBBB).	  (Figure	  6)	  119	  	  
	  
Female	  gender	  in	  acute	  cardiac	  care	   32	  
Figure	  6	  	  	   Elements	  of	  the	  TIMI	  risk	  score	  119	  
	  
(DM=diabetes	  mellitus,	  HTN=	  hypertension,	  SBP=	  systolic	  blood	  pressure,	  HR=	  heart	  rate,	  STE=	  ST-­‐segment	  
elevation,	  LBBB=	  left	  bundle	  branch	  block,	  rx=	  revascularisation,	  hrs=	  hours)	  
	  
Female gender was added to this multivariable model. (Aim	  A) We further 
adjusted for age (continuous variable) in the subgroup of patients <65 and ≥65 years-
of-age. (Aim	  D)	  The predictive discriminatory capacity of the TIMI risk score was 
expressed as the c-statistic, which represents the area under the Receiver Operating 
Characteristic (ROC), calibration was assessed by using the Hosmer-Lemeshow 
goodness-of-fit test. We established a logistic model for in-hospital mortality, 
including the TIMI risk score, gender and an interaction term between both. (Aim	  A)
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Aim	  B:	  Multivariable logistic-regression analysis was used to determine the 
independent predictors of renal dysfunction (defined as an 
eGFR<60mL/min/1.73m2) at admission including following covariates in the model: 
gender, age, bodyweight <67 kg, history of CAD, history of peripheral artery disease, 
hypertension and diabetes. Separate logistic regression analyses were performed 
regarding in-hospital mortality for each gender, including TIMI risk score as a 
continuous and renal dysfunction as a dichotomous variable in the model. 
Multivariable logistic regression analysis was also used to assess a possible 
interaction between gender and renal dysfunction regarding in-hospital mortality 
adding gender as a dichotomous variable and the product of gender and renal 
dysfunction as an interaction term to the previous model. 
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III.2	   AHF	  patients	  
Dataset:	  
The BIO-HF registry is a prospective HF-registry evaluating all patients 
admitted with New York Heart Association (NYHA) class III-IV in 2 Belgian 
hospitals (AZ Maria-Middelares Ghent hospital and the UZ VUB Brussels). 129 The 
objective of the registry is to prospectively collect data regarding baseline 
characteristics, in-hospital treatment, therapy at discharge and outcome for 
consecutive patients with AHF treated in these hospitals. From November 2006 to 
May 2012 a total of 977 patients were included in the registry.  
Data regarding AF on admission were missing in 20 patients. AF occurred in 
432 of the remaining 957 patients. Clinical and echocardiographic data as well as data 
on therapy for HF and AF, before, during and at discharge were recorded in all 
patients. Risk factors and comorbidities were documented.  
The central ethical committee of the UZ Brussels and the Maria Middelares 
Hospital Ghent approved the BIO-HF database. (2010/262). We received local Ethical 
Committee approval for this study as well as informed consent from the patients or 
their relatives. 
Statistical	  analysis	  
Multivariable logistic regression analysis was used to determine the 
independent predictors of AF on admission, including the following covariates in the 
model: sex, age (continuous variable), hypertension, diabetes, anaemia, renal 
dysfunction, HF with reduced ejection fraction (HF-REF, defined as an EF<50%), left 
atrial diameter, CAD, peripheral artery disease, and mitral valve regurgitation (MR) 
> grade 2. To evaluate the composite of 1-year mortality and re-hospitalisation 
following covariates were included in the multivariable analysis: female gender, 
variables that were associated with the endpoint in a univariate analysis in this 
database (age, admission heart rate, renal dysfunction, β-blocker at discharge, 
vitamin K antagonists at discharge, angiotensin-converting enzyme inhibitor [ACE-I] 
or angiotensin receptor blocker [ARB] at discharge, aldosterone receptor antagonist 
[ARA] at discharge) and variables that were different between sexes in univariate 
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analysis in this database (age, hypertension, renal dysfunction, CAD, HF-REF, active 
smoking, COPD, and ARA at discharge).	  (Aim	  C)	  
The same analysis was done in the subgroup of patients < and ≥75 years-of-
age. To assess a possible interaction between sex and age regarding the primary end 
point, the product of sex and age (continuous variable) was added as an interaction 
term to the previous model. (Aim	  D)	  
	  
III.3	  	   	  PPCM	  patients	  
We conducted a retrospective 10-year search (2000 to 2010) of the patient 
database of the department of Cardiology of the Ghent University Hospital for 
patients treated with mechanical support in the acute phase of PPCM. Diagnosis of 
PPCM was based upon development of symptoms of HF due to systolic dysfunction 
in the last month of pregnancy or within five months after delivery without any 
identifiable cause of HF or recognisable heart disease prior to the last month of 
pregnancy. Mechanical support was defined as ‘intra-aortic balloon pump’ (IABP), 
‘extra corporeal membrane oxygenation (ECMO) or ‘left ventricular assist device’ 
(LVAD).  
During this period 6 PPCM patients were treated with mechanical support. 
Demographic, clinical, hemodynamic and echocardiographic data as well as data on 
serology were evaluated. The outcomes of the different treatment strategies as well 
as their complications were evaluated. (Aim	  E) 
We received local ethical committee approval and informed consent from the 
patients or their relatives.  
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IV.	   Results	   	  
________________________________________________________	  
	  
IV.1	  	   Female	  gender	  in	  ST-­‐segment	  Elevation	  Myocardial	  Infarction	  	  	  
	  
IV.1.1	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  1:	  	  
Gender,	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  in-­‐hospital	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  4:	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  peripartum	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  and	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  to’	  
	  therapeutic	  options:	  a	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  with	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ABSTRACT	  
Background:	  The	  relationship	  between	  the	  predictive	  performance	  of	  the	  TIMI	  risk	  score	  for	  STEMI	  
and	  gender	  has	  not	  been	  evaluated	  in	  the	  setting	  of	  primary	  PCI	  (pPCI).	  Here,	  we	  compared	  in-­‐
hospital	  mortality	  and	  predictive	  performance	  of	  the	  TIMI	  risk	  score	  between	  Belgian	  women	  and	  
men	  undergoing	  pPCI.	  
Methods	  and	  Results:	  In-­‐hospital	  mortality	  was	  analysed	  in	  8,073	  (1,920	  [23.8%]	  female	  and	  6,153	  
[76.2%]	  male)	  consecutive	  pPCI-­‐treated	  STEMI	  patients,	  included	  in	  the	  prospective,	  observational	  
Belgian	  STEMI	  registry	  (January	  2007	  to	  February	  2011).	  A	  multivariable	  logistic	  regression	  model,	  
including	  TIMI	  risk	  score	  variables	  and	  gender,	  evaluated	  differences	  in	  in-­‐hospital	  mortality	  between	  
men	  and	  women.	  The	  predictive	  performance	  of	  the	  TIMI	  risk	  score	  according	  to	  gender	  was	  
evaluated	  in	  terms	  of	  discrimination	  and	  calibration.	  Mortality	  rates	  for	  TIMI	  scores	  in	  women	  and	  
men	  were	  compared.	  Female	  patients	  were	  older,	  had	  more	  comorbidities	  and	  longer	  ischaemic	  
times.	  Crude	  in-­‐hospital	  mortality	  was	  10.1%	  in	  women	  vs.	  4.9%	  in	  men	  (OR	  2.2	  [95%	  CI	  1.82-­‐2.66],	  
p<0.001).	  When	  adjusting	  for	  TIMI	  risk	  score	  variables,	  mortality	  remained	  higher	  in	  women	  
(OR=1.47	  [95%	  CI	  1.15	  to	  1.87],	  p=0.002).	  The	  TIMI	  risk	  score	  provided	  a	  good	  predictive	  
discrimination	  and	  calibration	  in	  women	  as	  well	  as	  in	  men	  (c-­‐statistic=	  0.84	  [95%	  CI	  0.809-­‐0.866],	  
goodness-­‐of-­‐fit	  p=0.53	  and	  c-­‐statistic	  =	  0.89	  [95%	  CI	  0.873-­‐0.907],	  goodness-­‐of-­‐fit	  p=0.13	  
respectively),	  but	  mortality	  prediction	  for	  TIMI	  scores	  was	  better	  in	  men	  (p=0.02	  for	  TIMI	  score	  x	  
gender	  interaction).	  	  
Conclusions:	  In	  the	  Belgian	  STEMI-­‐registry,	  pPCI-­‐treated	  women	  had	  a	  higher	  in-­‐hospital	  mortality	  
rate	  even	  after	  correcting	  for	  TIMI	  risk	  score	  variables.	  The	  TIMI	  risk	  score	  was	  effective	  in	  predicting	  
in-­‐hospital	  mortality	  but	  performed	  slightly	  better	  in	  men.	  	  
Clinical	  trial	  registration:	  The	  database	  was	  registered	  with	  clinicaltrials.gov	  (NCT00727623)	  
Key	  words:	  STEMI,	  gender,	  primary	  PCI,	  TIMI	  risk	  score,	  in-­‐hospital	  mortality	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INTRODUCTION	  
Cardiovascular disease is the major cause of death in women over the age of 
65. Since the early nineties, higher mortality rates have been reported for women 
with ST-segment elevation myocardial infarction (STEMI) as compared to men. 54, 56, 70, 77, 
109, 110, 130 The poorer outcome in women has been attributed to a higher age, more 
advanced disease, more comorbidities, longer ischaemic times, worse clinical 
condition on presentation and the underuse of evidence-based therapy and invasive 
reperfusion strategies. 83, 109 Several authors demonstrated that sex-related mortality 
differences are confined to younger patients, typically those younger than 50 years-
of-age. 65, 77, 131 Despite the fact that pPCI improves outcome in STEMI in both men and 
women 132, as confirmed by the current guidelines 60, there is conflicting evidence 
regarding gender-based differences in the short-term outcome in women treated 
with pPCI. In 2001, Vakili et al. demonstrated that women treated with pPCI for a 
first STEMI still had a higher risk of death as compared to men. 111 This finding was 
confirmed in some studies 112, 113, while others found no significant sex-related 
differences in early mortality. 70, 114-118, 122 
The Thrombolysis In Myocardial Infarction (TIMI) risk score for STEMI is a 
simple arithmetic score that predicts short-term mortality based on age and clinical 
data on admission. 119 This score was initially developed and validated in a 
randomised controlled trial of patients treated with fibrinolysis but proved to be 
useful in patients treated with pPCI in an observational registry (c-statistic= 0.80 for 
patients treated with pPCI in the NRMI III registry [n=15,348]). 133 Ten baseline 
variables accounted for 97% of the predictive capacity and were constituted in the 
TIMI risk score. Female gender was not included in the TIMI risk score, as it was one 
of the 5 variables accounting for the remaining 3% of the predictive capacity for 30- 
day mortality (OR=1.2; 95% CI 1-1.2). There are no data on the predictive 
performance of the TIMI risk score when applied to a community-based cohort of 
men and women in the current era of pPCI, stenting and contemporary adjunctive 
antiplatelet therapy. 
Accordingly, we compared the in-hospital mortality rate and predictive 
performance of the TIMI risk score between male and female Belgian STEMI patients 
undergoing pPCI. 
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METHODS	  
Belgian	  STEMI	  registry	  
The Belgian STEMI registry is a prospective observational registry of 
unselected Belgian STEMI patients from 72 Belgian hospitals. STEMI was defined as 
follows: symptoms suspicious of acute coronary syndrome, combined with ST-
elevation (>1mm in 2 continuous leads) or new left bundle branch block (LBBB) on 
ECG. The registry contains demographics (zip code, PCI vs. no PCI centre), previous 
history (diabetes, hypertension, peripheral artery disease, coronary artery disease 
[CAD]), clinical characteristics at admission (weight < or ≥ 67 kg, admission blood 
pressure < or ≥ 100 mmHg, admission heart rate > or ≤ 100 bpm), infarct localisation 
(anterior, LBBB, non anterior), practice patterns (treatment, transfer, ischaemic and 
intervention times) and in-hospital outcomes. Ischaemic time is defined as the time 
between onset of symptoms and revascularisation therapy. The registry is an 
initiative from the Belgian Working Group on Acute Cardiology (BIWAC) and is 
supported by the Belgian government and the Belgian College of Cardiologists. All 
Belgian cardiologists working in hospitals with acute care facilities were required to 
prospectively collect data on all admitted STEMI patients starting from January 2007. 
Since a patient file can only be finalised when all required data are provided, there 
are no missing covariates in the registry. The database was registered with 
clinicaltrials.gov (NCT00727623). This study was approved by the central ethical 
committee of the Ghent University Hospital (2011/455). Informed consent was 
obtained from all patients or their legal representatives.  
During the period between January 2007 and February 2011, a total of 9,535 
STEMI patients from 72 hospitals (25 with PCI facilities and 47 without PCI facilities) 
were prospectively included. Of these, 8,073 (84.67%) patients were treated with 
pPCI <24 hours after hospital admission and included in the analysis. Patients 
receiving rescue PCI after failed thrombolysis (N=272, 2.85%) were not included in 
the PCI group, while patients who underwent facilitated PCI (N= 231, 2.42%) were 
included in the PCI group. A yearly audit, conducted by an external commission, of 
10% of all patient files was performed to verify the validity of the data. Data were 
electronically collected via a protected eCRF. The database is managed by an 
independent electronic data-capture provider (Lambda Plus, SA, Gembloux, 
Belgium).  
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Clinical	  End	  Points	  
The primary endpoint of the study was in-hospital mortality.  
	  
TIMI	  risk	  score	  
The TIMI risk score was automatically calculated from 8 differentially 
weighted clinical indicators ascertained upon admission. The TIMI score ranges from 
0 to 14 and is calculated as follows: age (2 points: 65-74, 3 points: 75 and older); 
history of angina, diabetes or hypertension (1 point); admission systolic blood 
pressure (BP) <100 mmHg (3 points); admission heart rate (HR) >100 beats/min 
(bpm) (2 points); admission Killip class >I (2 points); admission weight <67 kg (1 
point); anterior infarction or LBBB (1 point); and time to reperfusion therapy > 
4hours (1 point). 119 
	  
Statistical	  Analysis	  
We compared the baseline characteristics and in-hospital outcomes of women 
with those of men. Categorical variables were compared with the Fisher’s exact test. 
Continuous variables were evaluated for normality. The Student’s t test was used for 
continuous variables with a normal distribution (presented as the mean ± SD), and 
Mann Whitney-U test was used for continuous variables (presented as the median 
and interquartile range [IQR]) without a normal distribution.  
We created a multivariable logistic regression model to evaluate the 
relationship between gender and in-hospital mortality; including all TIMI risk score 
variables: age-group (< and ≥65 years-of-age), history of hypertension, history of 
diabetes, previous CAD, Killip Class >I, ischaemic time >4h, admission BP <100 
mmHg, admission HR >100 bpm, weight <67 kg, anterior myocardial infarction or 
LBBB). Female gender was added to this multivariable model. Odds Ratios (OR) with 
95% confidence intervals (CI) are reported. Statistical significance was defined as 
p<0.05 or CI for OR that did not include 1.0.  
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The predictive discriminatory capacity of the TIMI risk score was expressed as 
the c-statistic, which represents the area under the ROC (receiver operating 
characteristic: 0.50 indicating chance discrimination and 1.00 perfect discrimination) 
curve for predicting in-hospital mortality in both men and women. Calibration was 
assessed by using the Hosmer-Lemeshow goodness-of-fit test; a p-value > 0.05 was 
pre-specified as good calibration. We established a logistic model for in-hospital 
mortality, including the TIMI risk score, gender and an interaction term between 
both.  
All statistical analyses were performed using the PASW 18 statistical software 
(SPSS Inc., Chicago, IL, USA). 
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RESULTS	  
Baseline	  characteristics	  
Baseline patient characteristics are shown in	  Table	  1.	  During the period 
between January 2007 and February 2011, 8,073 patients were treated with pPCI: 
1,920 (23.8 %) were female and 6,153 (76.2%) were male. TIMI risk scores at 
admission were higher in women vs. men (TIMI: median 5 [IQR 3-7] vs. 3 [IQR 2-5], 
p<0.001). As compared to men, the women were older (mean age 68.2 vs. 60.7 years, 
p<0.001) and more had diabetes (18.5% vs. 14.1%, p<0.001), hypertension (55% vs. 
39.9%, p<0.001) and body weights <67 kg (42.6% vs. 8.9%, p<0.001). Furthermore, 
less of these women had previous CAD as compared to men (15.3% vs. 19.9%, 
p<0.001). Women had longer total ischaemic times (ischaemic time >4 h in 45.8% of 
the female patients vs. 36.5% of the male patients, p<0.001). The need for CPR was 
not different between women and men (11.5% vs. 10.8%, p=0.41).  The Killip class at 
admission was higher in women vs. men (Killip >I: 28.3% vs. 19.9%, p<0.001). 
Women also experienced longer door to balloon times (DTB) as compared to men: 
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Table	  1	  	   Baseline	  characteristics	  
Characteristic	   Women,	  N=1,920	  (28.3%)	   Men,	  N=6,153	  (76.2%)	   p-­‐value	  
TIMI	  score,	  median	  [IQR]	   5	  [IQR	  3-­‐7]	   3	  [IQR	  2-­‐5]	   <0.001	  
Mean	  age,	  years	  (SD)	   68.2	  (13.6)	   60.7	  (12.5)	   <0.001	  
Age	  <65	  years	   15.4	   84.6	   	  
Age	  65-­‐75	  years	   27.1	   72.9	   	  
Age	  >75	  years	   44.3	   55.7	   	  
Diabetes	   18.5	   14.1	   <0.001	  
Hypertension	   55	   39.9	   <0.001	  
Weight	  <67	  kg	   42.6	   8.9	   <0.001	  
Previous	  CAD	   15.3	   19.9	   <0.001	  
Ischaemic	  time	  >4h	   45.8	   36.5	   <0.001	  
CPR	   11.5	   10.8	   0.41	  
HR	  >100bpm	   16.8	   13.1	   <0.001	  
BP	  <100mmHg	   23.7	   18.7	   <0.001	  
Ant.	  AMI	  or	  LBBB	   46.3	   44.4	   0.10	  
Killip	  Class	   	   	   <0.001	  
I	   71.8	   80.1	   	  
II	   13.3	   10.1	   	  
III	   4.1	   2.9	   	  
IV	   10.9	   6.8	   	  
Total	  Ischaemic	  time	   	   	   <0.001	  
<2h	   16.2	   21.7	   	  
2-­‐4h	   38.0	   41.9	   	  
4-­‐8h	   22.3	   18.9	   	  
8-­‐12h	   7.6	   6.2	   	  
12-­‐24h	   9.1	   6.8	   	  
>24h	   6.8	   4.6	   	  
Door-­‐to-­‐balloon	  time	   	   	   0.003	  
DTB	  <60min	   50.5	   55	   	  
DTB	  ≥60	  and	  <120min	   36.1	   33.1	   	  
DTB	  ≥120min	   13.4	   11.9	   	  
CAD=	  coronary	  artery	  disease	  ,	  h=	  hour,	  CPR=	  cardiopulmonary	  resuscitation	  ,	  HR=	  heart	  rate	  ,	  bpm=	  beats	  per	  minute,	  BP=	  systolic	  blood	  pressure,	  Ant.	  AMI=	  	  
anterior	  acute	  myocardial	  infarction	  ,	  LBBB=	  left	  bundle	  branch	  block,	  DTB=	  door	  to	  balloon	  time,	  min=	  minutes.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Data	  are	  presented	  as	  percentage	  of	  patients	  unless	  otherwise	  specified	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Gender	  and	  in-­‐hospital	  mortality	  
The in-hospital mortality rate for the entire cohort of pPCI treated patients 
was 6.1 %. Crude mortality data show that mortality was double in invasively-
managed Belgian women with STEMI as compared to men (10.1% vs. 4.9%; OR= 2.2 
[95% CI 1.82-2.66], p<0.001). In a multivariable regression model, adjusting for TIMI 
risk score variables and gender, the disparity in the risk of death between men and 
women persisted (OR=1.47 [95% CI 1.15-1.87], p=0.002). Age ≥65 (OR=2.42 [95% CI 
1.92- 3.06], p<0.001), HR >100 bpm at admission (OR=1.60 [95% CI 1.27-2.01], 
p<0.001), BP at admission <100 mmHg (OR=3.54 [95% CI 2.81-4.46], p<0.001), known 
CAD (OR=1.28 [95%CI 1.00-1.63], p=0.05) and a Killip class >1 (OR=9.63 [95% CI 7.33 
to 12.64], p<0.001) were other independent predictors of in-hospital mortality, while 
hypertension (OR=1.00 [95% CI 0.80-1.25], p=0.98), diabetes (OR=1.16 [95% CI 0.88-
1.51], p=0.29) and an ischaemic time> 4h (OR=1.17 [95% CI 0.95-1.45], p=0.14) were 
not. Interaction tests for each individual TIMI risk score variable and gender 
demonstrated that an admission heart rate >100 bpm, an admission systolic blood 
pressure <100 mmHg and a Killip class >I had more effect on mortality in male than 
in female patients. (Table	  2)	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Table	  2	  	   Odds	  Ratios	  for	  in-­‐hospital	  mortality	  among	  patients	  undergoing	  	  	  
	   	   pPCI	  for	  STEMI	  after	  multivariable	  adjustment	  
Variable	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Women	  
OR	  (95%CI),	  p-­‐value	  
Men	  
OR	  (95%CI),	  p-­‐value	  
All	  
OR	  (95%CI),	  p-­‐value	  
Interaction	  gender	  
p-­‐value	  
Female	  gender	   	   	   1.47	  (1.15-­‐1.87),	  0.002	   	  
Age	  	  ≥65	  y	   2.32	  (1.51-­‐3.58),	  <0.001	   2.46	  (1.87-­‐3.25),	  <0.001	   2.42	  (1.92-­‐3.06),	  <0.001	   0.72	  
Weight	  <67	  kg	   1.02	  (0.72-­‐1.45),	  0.90	   1.04	  (0.69-­‐1.56),	  0.85	   1.02	  (0.78-­‐1.33),	  0.89	   0.28	  
CAD	   1.10	  (0.72-­‐1.68),	  0.67	   1.35	  (1.00-­‐1.82),	  0.05	   1.28	  (1.00-­‐1.63),	  0.05	   0.37	  
AHT	   1.13	  (0.78-­‐1.64),	  0.52	   0.93	  (0.70-­‐1.23),	  0.59	   1.00	  (0.80-­‐1.25),	  0.98	   0.78	  
DM	   1.10	  (0.72-­‐1.67),	  0.67	   1.24	  (0.87-­‐1.75),	  0.23	   1.16	  (0.88-­‐1.51),	  0.29	   0.90	  
HR	  >100	  bpm	   1.35	  (0.93-­‐1.98),	  0.12	   1.75	  (1.31-­‐2.34),	  <0.001	   1.60	  (1.27-­‐2.01),	  <0.001	   0.01	  
BP	  <100	  mmHg	   3.36	  (2.32-­‐4.88),	  <0.001	   3.66	  (2.72-­‐4.92),	  <0.001	   3.54	  (2.81-­‐4.46),	  <0.001	   0.04	  
Ischemic	  time	  >4	  h	   1.01	  (0.72-­‐1.43),	  0.95	   1.28	  (0.98-­‐1.68),	  0.07	   1.17	  (0.95-­‐1.45),	  0.14	   0.79	  
Killip	  Class	  >1	   8.14	  (5.31-­‐12.5),	  <0.001	   10.70	  (7.50-­‐15.25),	  <0.001	   9.63	  (7.33-­‐12.64),	  <0.001	   0.04	  
Ant.	  AMI	  or	  LBBB	   1.04	  (0.73-­‐1.47),	  0.84	   1.38	  (1.05-­‐1.81),	  0.02	   1.24	  (1.00-­‐1.54),	  0.05	   0.75	  
Y=year,	  kg=	  kilogram,	  CAD=	  coronary	  artery	  disease,	  AHT=	  arterial	  hypertension,	  DM=diabetes	  mellitus,	  HR=	  heart	  rate,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
bpm=	  beats	  per	  minute,	  BP=	  systolic	  blood	  pressure,	  h=	  hour,	  Ant.	  AMI=	  anterior	  myocardial	  infarction,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
LBBB=	  left	  bundle	  branch	  block	  
	  
Gender	  and	  TIMI	  risk	  score	  performance	  	  
The median TIMI risk score for all patients treated with pPCI was 4; women 
had a higher median TIMI risk score than men (TIMI score 5 [IQR 3-7] vs. 3 [IQR 2-
5]). More than half of the men, versus only a quarter of the women, had a TIMI risk 
score below 4 (54.1% vs. 27.6% of the women). Almost 17% of the women had a very 
high TIMI risk score (>8) as compared to only 7.5% of the men.	  (Figure	  1)
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Figure	  1.	  	  	   TIMI	  risk	  score	  distribution	  in	  male	  and	  female	  patients	  	  
	  	  
TIMI=	  The	  Thrombolysis	  In	  Myocardial	  Infarction	  (TIMI)	  risk	  score	  for	  STEMI	  
Calculation	  of	  TIMI	  score	  (0-­‐14):	  age	  (2	  points:	  65-­‐74,	  3	  points:	  75	  and	  older);	  history	  of	  angina,	  diabetes	  or	  
hypertension	  (1	  point);	  admission	  systolic	  blood	  pressure	  <100	  mmHg	  (3	  points);	  admission	  heart	  rate	  >100	  
beats/min	  (2	  points);	  admission	  Killip	  class	  >I	  (2	  points);	  admission	  weight	  <67	  kg	  (1	  point);	  anterior	  infarction	  
or	  LBBB	  (1	  point);	  time	  to	  reperfusion	  therapy	  >	  4	  hours	  (1	  point).	  
Dark	  grey	  bars	   =	  men	  	  
Light	  grey	  bars	   =	  women	  
	  
 
The in-hospital mortality rate increased with increasing TIMI risk scores in 
both women and men. (Figure	  2)	  The mortality rate difference between men and 
women was the highest for low TIMI risk scores (TIMI score ≤4) and in patients with 
TIMI scores >8. The mortality rate in women was higher for almost all TIMI risk 
scores.  
The TIMI risk score provided a good prognostic discrimination of mortality 
among both women (c-statistic = 0.84 [95% CI 0.809-0.866]) and men (c-statistic = 0.89 
[95% CI 0.873-0.907]). TIMI risk score calibration was good in both genders with a 
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Hosmer-Lemeshow goodness-of-fit of respectively p= 0.53 in women and p= 0.13 in 
men.  When comparing mortality rates for TIMI risk scores between women and 
men, with an interaction term for TIMI score and gender, we found that mortality 
prediction for TIMI score was better in men compared to women (p=0.02 for TIMI 
score x gender interaction).  
Figure	  2.	  	  	   In-­‐hospital	  mortality	  by	  TIMI	  risk	  score	  in	  male	  and	  female	  patients	  
	  
TIMI=	  The	  Thrombolysis	  In	  Myocardial	  Infarction	  (TIMI)	  risk	  score	  for	  STEMI	  
Calculation	  of	  TIMI	  score	  (0-­‐14):	  age	  (2	  points:	  65-­‐74,	  3	  points:	  75	  and	  older);	  history	  of	  angina,	  diabetes	  or	  
hypertension	  (1	  point);	  admission	  systolic	  blood	  pressure	  <100	  mmHg	  (3	  points);	  admission	  heart	  rate	  >100	  
beats/min	  (2	  points);	  admission	  Killip	  class	  >I	  (2	  points);	  admission	  weight	  <67	  kg	  (1	  point);	  anterior	  infarction	  
or	  LBBB	  (1	  point);	  time	  to	  reperfusion	  therapy	  >	  4	  hours	  (1	  point).	  
	  
Dark	  grey	  bars	  	  =	  men	  
Light	  grey	  bars	   =	  women	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Gender	  and	  age	  	  
The <65 years-of-age group  (n= 4,605) comprised 708 (18.3%) female patients, 
as compared to 1,212 (34.9%) female patients in the ≥65 years-of-age group (n= 
3,468). Adjusting for TIMI risk score variables (except age ≥65 year) and gender, 
demonstrated a sustained association between female gender and mortality in both 
age groups (<65 years-of-age: OR =1.71 [95% CI 1.05-2.77], p=0.03; ≥ 65 years-of-age: 
OR=1.39 [95% CI 1.05-1.83], p=0.02). After further adjustment for age in these age 
groups female gender remained a predictor for mortality in the <65 years-of-age 
group (<65 years: OR=1.73 [95% CI 1.07-2.82], p=0.03) but not in the ≥ 65 years-of-age 
group (≥ 65 years: OR=1.27 [95% CI 0.96-1.68], p=0.09). 
Gender	  and	  body	  weight	  	  
Overall, 60% of the patients with body weights <67 kg and 16.4% of the 
patients with body weights ≥67 kg were women. The adjusted mortality difference 
between women and men remained significant in the subgroup with body weights 
≥67 kg (OR=1.55 [95% CI 1.16-2.06], p=0.003) but not in the subgroup with body 
weights <67 kg (OR=1.29 [95% CI 0.82-2.01], p=0.27).  
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DISCUSSION	  
There is on-going debate whether gender itself is an independent predictor of 
in-hospital mortality in STEMI patients undergoing pPCI and the relationship 
between the predictive performance of the TIMI risk score for STEMI and gender has 
not been evaluated in this setting.  
We demonstrated that female patients, from a nationally representative 
(Belgium) community-based registry of 8,073 consecutive STEMI patients reperfused 
with pPCI, had a higher in-hospital mortality rate than men. Even after adjusting for 
the baseline risk variables of the TIMI risk score for STEMI, the risk of dying 
remained almost 50% higher in women. We showed that the TIMI risk score for 
STEMI, which weighs these different risk factors, demonstrated a good prognostic 
discrimination and calibration in both men and women treated with pPCI, but the 
mortality prediction for TIMI risk score was better in men. 
Several factors may contribute to the worse outcome of women experiencing a 
STEMI: first women are older and have more co-morbidities, including diabetes and 
hypertension and this has been observed consistently in different trials and registries. 
56 Women seek treatment with later stage STEMI 134 and suffer longer door-to-
balloon/-needle times 135, resulting in longer ischaemic times and more myocardium 
at risk. 136 Women generally have a lower body weight and hence a lower BSA, which 
is not only a risk factor for bleeding complications after PCI 137 but is also associated 
with a higher mortality. This is also known as the ‘obesity paradox’. 138 Less frequent 
use of evidence-based management therapies, including invasive management, more 
extensive CAD and smaller coronary arteries, or a higher risk of peri-procedural 
complications may also contribute to their poorer outcome. 83, 135 In general, the 
question remains whether gender-related differences in outcome would persist if 
both men and women presenting with STEMI received the same evidence-based 
management, including pPCI as the current standard. Several investigators have 
addressed this question during the last two decades. However, sample sizes were 
often small, and these studies do not always reflect the current standards of stenting 
and adjunctive antiplatelet therapy.  
We demonstrated that an age ≥ 65 years is an important predictor of mortality. 
A significant gender related mortality rate difference was observed in the  <65 years-
of-age group as well as in the ≥ 65 years-of-age group. After further adjustment for 
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age in these age groups, the mortality gap persisted in the <65 years-of-age 
suggesting that age alone does not fully explain the difference in outcomes between 
women and men, especially not in the patient group <65 years-of-age. Moreover the 
mortality gap in this group warrants close monitoring of these women in the acute 
phase. 
Although diabetes and hypertension are two of the main risk factors for 
developing an ACS these conditions were no independent predictors of in-hospital 
mortality, not for the entire cohort or separately between women and men. The fact 
that diabetes was not associated with increased in-hospital mortality might be 
explained by a greater risk reduction with pPCI in diabetic patients as compared to 
non-diabetic patients 139 and is consistent with the findings of Meisinger et al. who 
showed only an association with long-term mortality, particularly in women. 140 There 
appeared to be no clear association between a history of hypertension and in-hospital 
mortality among STEMI patients. We presume that many patients with known 
hypertension already receive adequate treatment, including cardio-protective 
medication (ACE-inhibitors, statins, aspirin) while patients with unknown 
hypertension were classified in the registry as having no history of hypertension. 141, 142 
Although more prevalent among women, diabetes and hypertension also did not 
account for the higher in-hospital mortality among women in our population.  
We confirmed that women sought treatment with later stage STEMI as 
compared to men and experienced longer ‘door to-balloon-times’, which resulted in 
longer total ischaemic times. One of the reasons behind this later presentation is the 
lack of typical chest pain, especially in younger women suffering a myocardial 
infarction, as was recently demonstrated in the National Registry of Myocardial 
Infarction. 25 Another problem is the lack of awareness at the physician level: doctors 
can be misled by this atypical presentation and/or underestimate the possibility of 
an acute coronary syndrome, especially in young women. This may lead to delays in 
diagnosis and treatment as well as suboptimal treatment. Other reasons for the later 
stage presentation and longer door-to-balloon time remain unclear but are one of the 
reasons behind awareness campaigns addressing females around the world. After 
multivariable analysis, an ischaemic time >4 hours was not an independent predictor 
of in-hospital mortality, however an ischaemic time >4 hours may influence other 
TIMI variables such as Killip class and haemodynamic compromise.  
Female	  gender	  in	  acute	  cardiac	  care	   54	  
Finally female Belgian STEMI patients more frequently had a body weight <67 
kg and were sicker on admission, as reflected by their higher Killip class and 
prevalence of admission hypotension and tachycardia; correction for all of these 
differences, all included in the TIMI risk score, also failed to explain the differences in 
in-hospital mortality rates between men and women. However interaction tests for 
each predictor with gender demonstrated that a HR  >100bpm, a BP <100mmHg and 
a Killip class >1 had more effect on mortality in men than in women.   
After correction for all of the TIMI risk score variables, the mortality rate 
remained significantly higher in women as compared to men. On the other hand, our 
analysis showed that the TIMI risk score provides good predictive discrimination in 
both genders in a community-based population treated with primary angioplasty.  
The mortality prediction for TIMI risk score was slightly better in men. However, as 
pointed out by Vergouwe et al., comparing c-statistics between groups may be biased 
by the variation in patients risk profiles in these groups; the tighter interquartile 
range in the TIMI risk score distribution in men compared to women, seems rather 
inconsistent with this explanation. 143 There seemed to be a stronger impact of 
admission hypotension, admission tachycardia and a Killip class >I on mortality in 
men. (Table	  2)  
Despite the fact that the TIMI risk score was developed and validated in a 
randomised controlled trial of fibrinolysis, it is still a valuable tool to predict early 
mortality in currently treated male and female STEMI patients. It remains unclear 
whether the worse baseline haemodynamic profile in women (HR>100 bpm, 
BP<100mmHg and KILLIP >1), good for 7 points in the TIMI risk score, could be 
improved by reducing ischaemic times, and what impact this would have on gender 
differences in outcome after STEMI.  
Strengths	  and	  limitations:	  
This relatively large registry offers a “real life” view of the men and women 
treated with pPCI. Several limitations need to be considered when interpreting the 
results. First, the data were examined using risk adjustment models; however, we 
cannot exclude other confounding factors that were not registered, such as renal 
function, lipid status, smoking habits, coronary anatomy, TIMI flow rates, success of 
PCI, peri-procedural complications, treatment (anti-coagulation, antiplatelet agents, 
β-blockers, ACE-inhibitors, statins) or other unrecognised differences. Second, the 
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characterisation of some continuous important characteristics (body weight < or ≥ 67 
kg , ischaemic time, blood pressure and heart rate) into dichotomies was inherent to 
the registry and may have introduced residual confounding and hence biased our 
results to some extent. Third, we only collected data on in-hospital mortality rates; 
hence, it remains unclear whether our results can or cannot be extrapolated to long-
term outcomes. Furthermore, a referral bias for invasive evaluation is not excluded; 
secondary care centres that do not routinely apply pPCI for STEMI may refer only 
the most severely ill patients for urgent PCI. We found no significant differences in 
the baseline characteristics in female patients admitted in PCI vs. non-PCI hospitals 
to support this possibility. Finally, underreporting cannot be excluded despite the 
fact that the registry design called for consecutive enrolment of all STEMI patients.  
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CONCLUSIONS	  
Analysis of the Belgian STEMI registry demonstrates that almost a quarter of 
all patients treated with pPCI for ST-segment elevation myocardial infarction 
comprised women. In-hospital mortality rates of PCI-treated female STEMI patients 
were higher as compared to their male counterparts, even after adjustment for TIMI 
risk score variables. The TIMI score for STEMI proved to have a good predictive 
performance in both women and men in predicting in-hospital mortality rates in 
currently pPCI treated patients, however this predictive performance was slightly 
better in men than in women. The TIMI risk score remains a reliable and simple 
bedside score suitable for early risk stratification in women as well as in men. 
Reducing the time delays remains one of the most important modifiable factors that 
could improve TIMI risk scores and outcomes in women. This stresses the need for 
continuous awareness campaigns, especially in younger women, but also in the 
physicians confronted with these patients.   
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ABSTRACT	  
Background:	  Mortality	  in	  female	  patients	  with	  ST-­‐segment	  elevation	  myocardial	  infarction	  (STEMI)	  
undergoing	  primary	  angioplasty	  (pPCI)	  is	  higher	  than	  in	  men.	  We	  examined	  gender	  differences	  in	  the	  
prevalence	  and	  prognostic	  performance	  of	  renal	  dysfunction	  at	  admission	  in	  this	  setting.	  	  
Methods:	  A	  multicentre	  retrospective	  sub-­‐analysis	  of	  the	  Belgian	  STEMI-­‐registry	  identified	  1,638	  
patients	  (20.6%	  women,	  79.4%	  men)	  treated	  with	  pPCI	  in	  8	  tertiary	  care	  hospitals	  (January	  2007-­‐
February	  2011).	  The	  estimated	  glomerular	  filtration	  rate	  (eGFR)	  was	  calculated	  using	  the	  CKD-­‐EPI	  
equation.	  Main	  outcome	  measure	  was	  in-­‐hospital	  mortality.	  	  
Results:	  More	  women	  than	  men	  suffered	  from	  renal	  dysfunction	  at	  admission	  (42.3%	  vs.	  25.3%,	  	  
p<0.001).	  Mortality	  in	  women	  was	  doubled	  as	  compared	  to	  men	  (9.5	  vs.	  4.7%,	  OR=	  2.12	  [95%	  CI	  1.36-­‐
3.32],	  p<0.001]).	  In-­‐hospital	  mortality	  for	  men	  and	  women	  with	  vs.	  without	  renal	  dysfunction	  was	  
much	  higher	  (10.7	  and	  15.3	  vs.	  2.3	  and	  2.4%,	  p<0.001).	  In	  a	  multivariable	  regression	  analysis,	  
adjusting	  for	  age,	  gender,	  peripheral	  artery	  disease	  (PAD),	  coronary	  artery	  disease	  (CAD),	  
hypertension,	  diabetes	  and	  low	  body	  weight	  (<67	  kg),	  female	  gender	  was	  associated	  with	  renal	  
dysfunction	  at	  admission	  (OR=1.65	  [95%	  CI	  1.20-­‐2.25],	  p=0.002).	  In	  a	  multivariable	  model	  including	  
TIMI	  risk	  score	  and	  renal	  dysfunction,	  renal	  dysfunction	  was	  an	  independent	  predictor	  of	  in-­‐hospital	  
mortality	  in	  both	  men	  (OR	  =	  2.39	  [95%	  CI	  1.27-­‐4.51],	  p=0.007)	  and	  women	  (OR	  =	  4.03	  [95%	  CI	  1.26-­‐
12.92],	  p=0.02),	  with	  a	  comparable	  impact	  for	  men	  and	  women	  (p	  for	  interaction=0.69).	  
Conclusions:	  Female	  gender	  was	  independently	  associated	  with	  renal	  dysfunction	  at	  admission	  in	  
pPCI	  treated	  patients.	  Renal	  dysfunction	  was	  equally	  associated	  with	  higher	  in-­‐hospital	  mortality	  in	  
both	  men	  and	  women.	  
Keywords:	  
ST-­‐segment	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  glomerular	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  in-­‐hospital	  mortality,	  primary	  angioplasty	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BACKGROUND:	  
It has been demonstrated that women with STEMI undergoing primary PCI 
(pPCI) have higher odds for in-hospital mortality than men. Some authors 
demonstrated that this difference is likely explained by their older age and baseline 
comorbidities (especially hypertension and diabetes) 117, 118, 122, 144, 145, while other authors 
demonstrated a sustained mortality difference even after adjustment for appropriate 
confounders. 111-113 Chronic kidney disease, even mild, is associated with increased 
cardiovascular mortality. 146 More recently it was demonstrated that renal dysfunction 
is independently associated with in-hospital mortality in STEMI patients treated with 
pPCI. 120, 121, 147 
Data on gender differences in prevalence of renal dysfunction at admission in 
pPCI treated STEMI patients are scarce and have seldom been accounted for when 
evaluating gender differences in outcome, furthermore different definitions (serum 
creatinine levels vs. estimated Glomerular Filtration Rate [eGFR] values) and 
different methods of estimating creatinine clearance have been applied. 112, 118, 122, 123 
The GFR cannot be measured easily in clinical practice, instead it is estimated 
(eGFR) from equations, using variables such as serum creatinine level, age, body 
weight, race and sex. The most recent equation, the CKD-EPI equation (Chronic 
Kidney Disease Epidemiology Collaboration), published in 2009, is more precise and 
accurate than other equations such as the Cockroft-Gault, the MDRD (Modification 
of Diet in Renal Disease) and the re-expressed MDRD equation, especially at GFRs > 
60 mL/min/1.73m2. 124, 148 The CKD-EPI equation usually yields higher values for eGFR 
than the MDRD study equation, probably because it was developed in a more 
diverse study population, including participants with and without CKD. Therefore it 
is assumed that the CKD-EPI equation leads to smaller average bias in clinical 
populations with a wide range of GFRs, such as the STEMI population. 149 In a recent 
analysis of the PLATO trial, including 18,624 patients with an acute coronary 
syndrome, the CKD-EPI formula exhibited the highest prognostic value and 
produced a clinical relevant cut-off of 60 mL/min/1.73m2. 150 
The Thrombolysis In Myocardial Infarction (TIMI) risk score for STEMI is a 
simple arithmetic score that predicts short-term mortality based on age and clinical 
data on admission. 119 This score was initially developed and validated in a 
randomised controlled trial of patients treated with fibrinolysis but proved to be 
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useful in patients treated with primary PCI in an observational registry (c -statistic= 
0.80 for patients treated with primary PCI in the NRMI III registry [N=15,348]). 133 
Accordingly, we evaluated differences in prevalence of renal dysfunction at 
admission, defined as an eGFR<60mL/min/1.73m2, in men and women presenting 
with STEMI and treated with pPCI, using the CKD-EPI equation for assessment of 
eGFR. We assessed the prognostic impact of renal dysfunction at admission, on top 
of the TIMI risk score, on in-hospital mortality in men and women and finally we 
evaluated whether there was an interaction between female gender and renal 
dysfunction regarding in-hospital mortality.  
As far as we are aware this is the first study that investigates gender 
differences in prevalence and prognostic value of renal dysfunction, assessed by the 
CKD-EPI equation, in a subgroup of currently pPCI-treated STEMI patients included 
in a national STEMI-registry. 
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SUBJECTS	  AND	  METHODS	  
Study	  population:	  	  
The Belgian STEMI registry is a prospective observational registry of Belgian 
STEMI patients from 72 Belgian hospitals that contains demographics, clinical 
characteristics at admission, practice patterns and in-hospital outcomes. The registry 
is an initiative from the Belgian Working Group on Acute Cardiology (BIWAC) and 
is supported by the Belgian Government of Social Affairs and Public Health and the 
Belgian College of Cardiologists. Belgium constitutes a catchment area of 11.000.000 
persons. All Belgian cardiologists working in hospitals with acute care facilities were 
required to prospectively collect data on all admitted STEMI patients (symptoms 
suspicious of acute coronary syndrome, combined with ST-segment elevation or new 
LBBB on ECG) starting from January 2007.  
During the period January 2007 to February 2011, a total of 9,535 (24.7% 
women) patients from 72 hospitals (25 with PCI facilities and 47 without PCI 
facilities) were prospectively included in the STEMI registry. We retrospectively 
collected admission values of serum creatinine of patients (N= 1,751; 20.7% women) 
admitted in the eight tertiary care centres that participated in this sub-analysis. Of 
these 1,638 (20.6% women) were treated with primary PCI <24 hours after hospital 
admission and included in the analysis. (Figure	  1) 
A yearly audit, conducted by an external commission, of 10% of all patient 
files was performed to verify the validity of the data; the evaluation of these files 
demonstrated a 96% concordance rate between source documents and case report 
forms. Data were electronically collected via a protected eCRF. The database is 
managed by an independent electronic data-capture provider (Lambda Plus, SA, 
Gembloux, Belgium). 
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Figure	  1	  	  	   Study	  population,	  undergoing	  primary	  PCI	  in	  8	  (out	  of	  25)	  selected	  centres	  
	  
TIMI	  risk	  score	  
The TIMI risk score was automatically calculated from 8 differentially 
weighted clinical indicators ascertained upon admission. The TIMI score ranges from 
0 to 14 and is calculated as follows: age (2 points: 65-74, 3 points: 75 and older); 
history of angina, diabetes or hypertension (1 point); admission systolic blood 
pressure (BP) <100 mmHg (3 points); admission heart rate (HR) >100 bpm (2 points); 
admission Killip class >I (2 points); admission weight <67 kg (1 point); anterior 
infarction or LBBB  (1 point); and time to reperfusion therapy > 4hours (1 point). 119 
	  
GFR	  measurement	  
We defined renal dysfunction as an eGFR< 60 mL/min/ 1.73m2, 
corresponding to National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative (NKF KDOQI) stages 3 to 5 of chronic kidney disease. The eGFR was 
calculated using the CKD-EPI equation based on the admission value of serum 
creatinine 124 as follows:  
eGFR = 141 x min (Scr/k, 1)a x max (Scr/k, 1)-1.209 x 0.993age [ x 1.018 if female ] [ x 1.159 if 
black ], where Scr is serum creatinine, k is 0.7 for females and 0.9 for males, a is -0.329 
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for females and -0.411 for males. The eGFR could not be calculated in 11.9% of the 
cases, due to missing values. We found no differences in proportions of women or 
baseline characteristics between patients with and without missing values, except for 
the incidence of Cardio Pulmonary Resuscitation (CPR) (19.5% vs. 10.1%, p<0.001) 
and in-hospital mortality (9.7 vs. 5.1%, p=0.009). 
	  
Outcome	  data:	  
 The primary endpoint existed of in-hospital mortality 
	  
Statistical	  Analysis:	  
We compared the baseline characteristics, including renal dysfunction at 
admission, and in-hospital outcomes of women with those of men. Distributions of 
categorical variables were compared by using the Fisher exact test. Continuous 
variables were evaluated for normality. The Student’s t test was used for continuous 
variables with a normal distribution (presented as the mean ± SD), and the Mann 
Whitney-U test was used for continuous variables (presented as the median and 
interquartile range [IQR]) without a normal distribution. Multivariable logistic-
regression analysis was used to determine the independent predictors of renal 
dysfunction at admission including following covariates in the model: gender, age, 
bodyweight <67kg, history of coronary artery disease (CAD), history of peripheral 
artery disease (PAD), hypertension and diabetes. Separate logistic regression 
analyses were performed regarding in-hospital mortality for each gender, including 
TIMI risk score as a continuous and renal dysfunction as a dichotomous variable in 
the model. Multivariable logistic regression analysis was also used to assess a 
possible interaction between gender and renal dysfunction regarding in-hospital 
mortality adding gender as dichotomous variable and the product of gender and 
renal dysfunction as an interaction term to the previous model. All multivariable 
analyses were based on complete patient records.  
Adjusted Odds Ratios (OR) with 95% confidence intervals (CI) are reported. 
Statistical significance was defined as p<0.05 or 95% confidence intervals (CI) for OR 
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that did not include 1.0. All statistical analyses were performed using the SPSS 19 
statistical software.  
	  
Ethics	  approval:	  
This study was approved by the central ethical committee of the Ghent 
University Hospital (2011/455). Informed consent was obtained from all patients or 
their legal representatives.  
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RESULTS	  
Baseline	  characteristics:	  
During the period between January 2007 and February 2011, 1,638 patients 
were treated with primary PCI in eight participating centres. Of them 338 (20.6 %) 
were female and 1,300 (79,4%) were male. Baseline patient characteristics are shown 
in Table	  1. As compared to men, women were on average 7 years older and more had 
diabetes, hypertension, and a body weight <67 kg. Furthermore, less women had 
previous CAD as compared to men. The history of PAD between women and men 
was not different. Women had longer total ischaemic times. The need for CPR was 
not different between women and men. The Killip class and TIMI risk score at 
admission were higher in women vs. men. Door to balloon times (DTB) were 
comparable among women and men. 
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Table	  1	  	   Baseline	  characteristics	  (N=	  1,638)	  
Characteristic	   Women	  (N=338,	  20.6%)	   Men	  (N=1,300,	  79.4%)	   p-­‐value	  
Age,	  mean	  (SD),	  y	   68.8	  (12.7)	   61.6	  (12.0)	   <0.001	  
Diabetes	   21.3	   13.8	   <0.001	  
Hypertension	   54.7	   41.4	   <0.001	  
Weight	  <67kg	   42.3	   9.8	   <0.001	  
Previous	  CAD	   16.9	   22.4	   0.03	  
Previous	  PAD	   8.6	   8.4	   0.91	  
Ischemic	  Time	  >4h	   47	   35	   <0.001	  
Door	  to	  Balloon	  >120min.	   14.2	   11.8	   0.59	  
CPR	   11.2	   11.2	   1.00	  
HR	  >100bpm	   17.2	   11.5	   <0.001	  
BP	  <100mmHG	   23.7	   15.3	   <0.001	  
Anterior	  AMI	   49.4	   45.1	   0.16	  
Killip	  >I	   26.6	   14.3	   <0.001	  
TIMI	  score,	  med.	  [IQR]	   5	  [3.0-­‐7.3]	   3	  [2.0-­‐5.0]	   <0.001	  
Creatinine	  (mg/dL)	  med.	  [IQR]	   0.90	  [0.75-­‐1.10]	   1.00	  [0.84-­‐1.17]	   <0.001	  
eGFR	  <60mL/min/1.73m2	   42.3	   25.3	   <0.001	  
Y=	  years,	  kg=	  kilogram,	  CAD=	  coronary	  artery	  disease,	  PAD=	  peripheral	  artery	  disease,	  Ischaemic	  time=	  symptom	  to	  balloon	  time,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
CPR=	  cardiopulmonary	  resuscitation,	  HR=	  heart	  rate,	  bpm=	  beats	  per	  minute,	  BP=	  systolic	  blood	  pressure,	  AMI=	  acute	  myocardial	  infarction,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
eGFR=	  estimated	  glomerular	  filtration	  rate	  
Data	  are	  presented	  as	  percentage	  of	  patients	  unless	  otherwise	  specified	  
	  
Gender	  and	  renal	  dysfunction	  
Median creatinine values were higher in men vs. women (median creatinine in 
men 1.0 [0.84-1.17] vs. 0.9 [0.75-1.10] in women, p<0.001). Renal dysfunction, defined 
as an eGFR below 60mL/min/1.73m2 or a Chronic Kidney Disease (CKD) stage 3, 4 
or 5 was more frequently observed in female patients (42.4% vs. 25.3%, p<0.001). 
(Figure	  2) In a multivariable regression analysis, including age (/year), hypertension, 
diabetes, CAD or PAD and a body weight below 67 kg, female gender remained 
independently associated with renal dysfunction (OR=1.65 [95%CI 1.20-2.25], 
p=0.002). Age and PAD were two other powerful determinants of renal impairment 
(Age: OR =1.07 [95% CI 1.05-1.08], p<0.001, PAD: OR=1.89 [95% CI 1.26-2.84], 
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p=0.002). Coronary artery disease was borderline significant as a determinant of 
renal dysfunction (OR=1.35 [95% CI 1.00-1.82], p=0.05). (Table	  2) 
	  
Figure	  2	  	   Chronic	  Kidney	  Disease	  (CKD)	  stage	  at	  admission	  according	  to	  gender	  
	  	  
CKD	  1:	  Chronic	  Kidney	  disease	  class	  1:	  eGFR	  ≥	  90	  	   	   mL/min/1.73m2	  
CKD	  2:	  Chronic	  Kidney	  disease	  class	  2:	  eGFR	  ≥	  60	  -­‐	  <	  90	   mL/min/1.73m2	  
CKD	  3:	  Chronic	  Kidney	  disease	  class	  3:	  eGFR	  ≥	  30	  -­‐	  <	  60	   mL/min/1.73m2	  
CKD	  4:	  Chronic	  Kidney	  disease	  class	  4:	  eGFR	  ≥	  15	  -­‐	  <	  30	   mL/min/1.73m2	  
CKD	  5:	  Chronic	  Kidney	  disease	  class	  5:	  eGFR	  <	  15	   	   mL/min/1.73m2	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Table	  2	   Determinants	  of	  admission	  renal	  dysfunction	  and	  Odds	  Ratios	  after	  	  
	   	   multivariable	  adjustment	  
Variable	   OR	   95%CI	   p-­‐value	  
Female	  gender	   1.65	   1.20-­‐2.25	   0.002	  
Age	  (/y)	   1.07	   1.05-­‐1.08	   <0.001	  
Weight	  <67kg	   0.87	   0.61-­‐1.23	   0.87	  
CAD	   1.35	   1.00-­‐1.82	   0.05	  
PAD	   1.89	   1.26-­‐2.84	   0.002	  
AHT	   1.10	   0.84-­‐1.43	   0.49	  
DM	   0.97	   0.69-­‐1.36	   0.87	  
Y=	  year,	  kg=	  kilogram,	  CAD=coronary	  artery	  disease,	  PAD=peripheral	  artery	  disease,	  AHT=arterial	  hypertension,	  DM=diabetes	  
	  
	  
Gender,	  baseline	  renal	  dysfunction	  and	  in-­‐hospital	  mortality	  	  
The in-hospital mortality rate for the entire cohort of pPCI treated patients 
was 5.7 %. Mortality in women was doubled as compared to men (9.5 vs. 4.7%, OR= 
2.12 [95% CI 1.36-3.32], p<0.001). Mortality in patients with renal dysfunction at the 
time of hospital admission was much higher compared to those without (12.0% vs. 
2.3%, p<0.001). In-hospital mortality was comparable in men and women without 
renal impairment:  2.3% vs. 2.4%, while there was a non-significant trend for higher 
mortality in women with renal dysfunction compared to men with renal dysfunction 
(15.3% vs. 10.7%, p=0.18). (Figure	  3)  
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Figure	  3	  	  	  	   In-­‐hospital	  mortality	  according	  to	  gender	  and	  renal	  function	  
	  
	  
TIMI	  risk	  score	  and	  additive	  prognostic	  performance	  of	  baseline	  renal	  dysfunction	  in	  men	  
and	  women	  
In a multivariable regression analysis including gender, TIMI risk score and 
renal dysfunction, both TIMI risk score (OR=1.47 [95% CI 1.35-1.60]) and renal 
dysfunction (OR 2.71 [95% CI 1.56-4.69]) were strong predictors of in-hospital 
mortality; there was a trend towards higher mortality in women (OR 1.45 [95% CI 
0.8-2.63]).  
Adding renal dysfunction to the TIMI risk score in men and women 
separately in a multivariable logistic regression model demonstrated that renal 
dysfunction was an independent predictor of in-hospital mortality in both men 
(OR=2.39 [95% CI 1.27-4.51], p=0.007) and women (OR=4.03 [95% CI 1.26-12.92], 
p=0.02), the interaction test demonstrated that this impact was comparable for men 
and women (p=0.69).
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DISCUSSION	  
In a sub-analysis of the Belgian STEMI registry, including 20.3 % of Belgian 
STEMI patients undergoing pPCI for STEMI, we found that renal dysfunction at the 
time of hospital admission (eGFR<60mL/min per 1.73m2 or CKD class 3 or higher), 
assessed by the CKD-EPI formula, was a common finding and that more women 
(42.3%) than men (25.3%) suffered from this condition. As expected, a CKD class 3 or 
higher on admission was associated with in-hospital mortality, and this 
independently of the TIMI risk score. Although there was a trend towards higher 
mortality for women with renal dysfunction compared to men with this condition, 
we could not demonstrate a gender difference in the impact of renal dysfunction on 
in-hospital mortality.  
Despite the fact that male STEMI patients had a higher serum creatinine 
concentration at admission, the prevalence of renal dysfunction defined by an eGFR 
<60mL/min per 1.73m2 and assessed with the CKD-EPI formula was almost doubled 
in women as compared to men, even after correction for observed differences in age 
and risk profile between men and women.  The higher serum creatinine 
concentrations in men can easily be explained by the larger muscle mass, resulting in 
greater creatinine generation, and a higher serum creatinine concentration for a given 
GFR. This illustrates that serum creatinine values should not be used to evaluate 
gender differences in the impact of renal function on outcome. It is not completely 
clear why the incidence of renal dysfunction is higher in women, we cannot exclude 
that there are unknown confounders that may explain this difference.   
 Many authors have demonstrated that women with STEMI have a higher risk 
of in-hospital mortality and some, but not all, could explain this higher mortality 
based on age and the presence of more comorbidities, especially hypertension and 
diabetes. 117, 118, 122, 144, 145 Lawesson et al. recently demonstrated in a small single centre 
study, including 274 STEMI patients undergoing pPCI, that female gender was a 
strong and independent predictor of renal dysfunction and that renal dysfunction 
had a possibly higher impact on 1-year mortality in women (p for interaction= 0.08). 
123 We confirmed that renal dysfunction was more prevalent in pPCI treated women 
but we did not find a gender-impact on in-hospital mortality. Given the fact that the 
prevalence of renal dysfunction was independently related to female gender and that 
there was no difference in mortality between women and men with preserved renal 
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function we speculate that renal dysfunction could be an important reason why 
women with STEMI die more than men.  
 The presented data do not reveal why renal dysfunction was associated with 
worse outcome. There are numerous data that demonstrate that chronic kidney 
disease serves as an important modifier for outcome. Renal dysfunction may serve as 
a surrogate marker for general health and for unknown risk factors that may explain 
the worse outcome. Also renal dysfunction may be associated with complications, of 
which development of (contrast induced) acute kidney injury (AKI) and bleeding are 
the most likely to occur.151 By implementing routine calculation of eGFR, based on the 
CKD-EPI formula, high risk patients can be identified, and strategies for prevention 
of contrast induced AKI (bicarbonate administration, optimization of hemodynamic 
status and discontinuation of nephrotoxic drugs) 152 and other complications (e.g. 
bleeding) can be initiated. More over, evidence based therapies such as β-blockers, 
ACE-inhibitors and statins should not be withheld in this subgroup. 153 
Today it is not clear whether the prognostic performance of the currently most 
used simple and bedside risk scores could improve by adding eGFR to the model. 
Kidney function, represented by various cut-offs for serum creatinine but not by 
eGFR, is already incorporated in the GRACE risk score. 154 Kidney function is not 
incorporated at all in the TIMI risk score for STEMI and this might be one of the 
reasons why the GRACE risk score performed better in STEMI patients in a recent 
meta-analysis of 15 derivation studies and 17 validation studies. 155 Given our finding 
that serum creatinine underestimates renal dysfunction, especially in women, future 
risk stratification should preferably use the eGFR based kidney function estimates 
such as the CKD-EPI equation.  
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Strenghts	  and	  limitations:	  
This study is unique as it represents the first dataset that links gender, renal 
dysfunction, assessed by the CKD-EPI equation, and outcomes in a subgroup of PCI-
treated STEMI patients included in the Belgian STEMI registry. As 71.2% of this 
Belgian STEMI cohort presented with an eGFR>60mL/min/1.73 m2 , the use of the 
CKD-EPI equation was appropriate.  
The study has some limitations. First, we only studied patients who 
underwent pPCI in a subgroup of 8 tertiary care centres that participated in the 
Belgian STEMI registry; since it has been demonstrated that patients with renal 
failure have less access to invasive therapy, a selection bias is not excluded. 156 Second, 
it is uncertain whether renal dysfunction at the time of hospital admission represents 
a steady state condition of chronic kidney disease or whether there was also a 
component of AKI. Third, we only collected data on in-hospital mortality rates; 
hence, it remains unclear whether our results can be extrapolated to long-term 
outcomes. Finally, it is not clear how missing values could have influenced our 
results, however we found no differences in proportions of women and baseline 
characteristics, except for a higher incidence of CPR in the group with missing 
values. This and the higher in-hospital mortality in this group suggest that these 
patients were more severely ill and probably also had renal dysfunction at the time 
of hospital admission, which would have reinforced our findings.  
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CONCLUSIONS:	  
Renal dysfunction, defined as an eGFR < 60mL/kg per 1.73m2 was common in 
a subgroup of patients undergoing primary PCI for STEMI and female gender was 
independently associated with this condition. Renal dysfunction, independent of the 
TIMI risk score, was associated with higher in-hospital mortality rates in both men 
and women. There was no gender difference in the prognostic impact of renal 
dysfunction regarding in-hospital mortality. Glomerular filtration rates should 
routinely be assessed at baseline in these patients and these and not serum creatinine 
values should be accounted for when evaluating gender differences in outcome after 
STEMI. Whether eGFR, assessed by the CKD-EPI equation, could improve the 
prognostic performance of currently used bedside risk stratification models remains 
to be elucidated.   
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ABSTRACT	  
Background:	  Little	  is	  known	  about	  sex	  differences	  in	  the	  prevalence,	  treatment,	  and	  outcome	  of	  atrial	  
fibrillation	  complicating	  acute	  heart	  failure.	  	  
Methods	  and	  results:	  Among	  957	  patients	  (429	  women,	  528	  men),	  included	  in	  the	  BIO-­‐HF	  registry,	  
45.2%	  (N=194)	  of	  the	  women	  and	  45.1%	  (N=238)	  of	  the	  men	  were	  admitted	  with	  atrial	  fibrillation.	  
The	  primary	  endpoint	  was	  a	  composite	  of	  1-­‐year	  all-­‐cause	  mortality	  and	  hospitalisation	  for	  heart	  
failure.	  Adjusted	  1-­‐year	  mortality	  and	  hospitalisation	  rates	  were	  similar	  between	  sexes	  (women:	  
38.5%,	  men	  36.0%;	  OR	  for	  female	  gender=1.1	  [95%	  CI	  0.65-­‐1.86],	  p=	  0.71).	  A	  significant	  interaction	  
between	  female	  sex	  and	  age	  (p=	  0.002)	  was	  observed;	  with	  worse	  prognosis	  for	  women	  <75years	  
(OR=7.17	  [95%	  CI	  1.79-­‐28.66],	  p=0.005)	  compared	  with	  men	  <75years.	  No	  sex	  differences	  in	  in-­‐
hospital	  treatment,	  restoration	  of	  sinus	  rhythm	  (16.5%	  in	  women	  vs.	  14.2%	  in	  men,	  p=	  0.58)	  or	  in-­‐
hospital	  mortality	  (5.7%	  in	  women	  vs.	  6.7%	  in	  men,	  p=0.69)	  were	  observed.	  	  
Conclusions:	  Among	  patients	  hospitalised	  with	  acute	  heart	  failure,	  no	  sex	  differences	  in	  the	  
prevalence	  and	  management	  of	  atrial	  fibrillation	  were	  observed.	  In-­‐hospital	  mortality	  and	  the	  
composite	  of	  1-­‐year	  mortality	  and	  re-­‐hospitalisation	  were	  not	  different	  between	  sexes,	  but	  a	  
significant	  sex-­‐age	  interaction	  was	  observed,	  with	  worse	  outcome	  in	  women	  <75	  years	  versus	  men	  
<75	  years-­‐of-­‐age.	  	  
Key	  words:	  acute	  heart	  failure,	  atrial	  fibrillation,	  gender.	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INTRODUCTION	  
	   Acute heart failure (AHF) is one of the leading causes for urgent hospital 
admission in the adult population. In general, women comprise almost half of the 
patients hospitalised for AHF in the Western world. On average they are older and 
have other co-morbidities than men. Heart failure (HF) with preserved ejection 
fraction due to diastolic dysfunction predominates in women, whereas coronary 
artery disease (CAD) and ischaemic cardiomyopathy are more prevalent in men with 
HF. Despite sex differences in comorbidities and aetiology there seems to be no sex 
gap in both short- and long-term outcomes in large patient series. 32, 33, 35, 157 
Atrial fibrillation (AF) is more prevalent in patients with HF 125, furthermore 
AF and HF may interact: a rapid ventricular rate can trigger AHF, and HF increases 
atrial stretch which can make AF more resistant to therapy. Retrospective analysis of 
two randomised controlled trials suggested that patients with both HF and AF have 
an increased risk for HF exacerbation, hospitalisation for HF, and death. 101, 158 The risk 
for adverse outcome HF patients with AF has been demonstrated in those with 
reduced ejection fraction as well as those with preserved ejection fraction. 159 Overall 
prognosis seems to be worse in patients who develop HF first as opposed to patients 
who develop HF after AF. 160 Little is known about sex differences in AF on admission 
among patients hospitalised for AHF. In the Euro HF Survey II, the ALARM-HF 
survey and a registry by Opasich, AF on admission was more frequently seen in 
women (41.2%, 49 and 49.2%) than in men (37%, 42 and 40.6%) while in the larger 
ADHERE and OPTIMIZE-HF registries more men than women had a history of atrial 
arrhythmia (30 and 30.3 % in women vs. 31, 31.2 % in men). 31-33, 35, 37, 37 The Euro Heart 
Survey on AF demonstrated that women with AF had more comorbidities, more HF 
with preserved systolic function and received less rhythm control than men but that 
long-term outcomes were similar. 41 Women >65 years-of-age with AF have an 
increased risk of stroke compared with men, as incorporated in the CHA2DS2VASc 
score. 161, 162 
Here we compared the incidence and treatment of AF on admission between 
men and women admitted with AHF (BIO-HF registry, Belgium, November 2006-
May 2012). Furthermore, we compared in-hospital mortality as well as the composite 
of all cause 1-year mortality or re-hospitalisation for HF among all women and men 
with AF complicating AHF as well as in the subgroup of patients <75 years-of-age.  
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METHODS	  
Study	  population:	  	  
The BIO-HF registry is a prospective registry evaluating all patients admitted 
with New York Heart Association (NYHA) class III-IV in 2 hospitals in Belgium from 
November 2006 to May 2012. A total of 977 (542 male [55.5%] and 435 female [44.5%]) 
patients, admitted in the AZ Maria-Middelares Ghent hospital or the UZ VUB 
Brussels hospitals were included in the registry. AF was diagnosed according to the 
admission electrocardiogram; these data were missing in 20 patients. Clinical and 
echocardiographic data as well as data on therapy for HF and AF, before, during and 
at discharge were recorded in all patients. HF with preserved left ventricular 
function (HF-PEF) was defined as a left ventricular ejection fraction (LVEF) ≥50%, HF 
with reduced ejection fraction (HF-REF) was defined as a LVEF <50%. Risk factors 
and comorbidities (smoking, history of hyperlipidaemia, history of hypertension, 
diabetes, anaemia [women: haematocrit <36%, men: haematocrit <39%], chronic 
obstructive pulmonary disease [COPD, as described in the patients medical record], 
renal dysfunction on admission [defined as: eGFR [CKD-EPI] <60mL/min/1.73m2], 
CAD, peripheral artery disease [PAD], mitral valve regurgitation [MR] >grade 2, 
thyroid disease, earlier stroke, dementia, malignancy, history of AF and acute 
coronary syndrome [ACS]) were documented.  
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Figure	  1	  	  	   Flowchart	  of	  patients	  included	  in	  the	  BIO-­‐HF	  registry	  and	  selected	  for	  the	  
present	  analysis.	  	  
	  
AF=	  atrial	  fibrillation,	  FU=	  follow	  up,	  rehosp=	  rehospitalisation
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Outcome	  data: 
 The primary outcome measure was the composite of one-year all-cause 
mortality or readmission for HF. Secondary endpoints were in-hospital mortality and 
restoration of sinus rhythm at discharge. 
 
Statistical	  Analysis:	  
Data are presented in percentage for categorical variables and as mean and 
standard deviation for continuous variables. Distributions of categorical variables 
were compared with the use of the chi-square test. The 2-tailed Student t test was 
used to compare continuous variables. Multivariable logistic regression analysis was 
used to determine the independent predictors of AF on admission including the 
following covariates in the model: sex, age (continuous variable), hypertension, 
diabetes, anaemia, renal dysfunction, HF-REF, left atrial diameter, CAD, PAD, 
MR>grade 2. To evaluate the composite of one year mortality and re-hospitalisation, 
the following covariates were included in the multivariable analysis: sex, variables 
that were associated with the primary endpoint in a univariate analysis in this 
database (age, admission HR, renal dysfunction, β-blocker at discharge, vitamin K 
antagonists [VKA] at discharge, angiotensin-converting enzyme inhibitor [ACE-I] or 
angiotensin receptor blocker [ARB] at discharge, aldosterone receptor antagonist at 
discharge) and variables that were different between sexes in univariate analysis 
(age, hypertension, renal dysfunction, CAD, HF-REF, active smoking, COPD and 
aldosterone receptor antagonist at discharge). To assess a possible interaction 
between sex and age regarding the primary endpoint, the product of sex and age 
(continuous variable) was added as an interaction term to the previous model. The 
following variables had missing data: renal dysfunction (all: 1.4%, <75y: 1.7%, ≥ 75y: 
1.3%), LVEF<50% (all: 6.9%, <75y: 7.7%, ≥ 75y: 6.7%), admission heart rate (all: 0.7%, 
<75y: 0.9%, ≥ 75y: 0.6%) and COPD (all: 5.8%, <75 y: 5.1%, ≥ 75y: 6.0%).  
Adjusted Odds Ratios (OR) with 95% confidence intervals (CI’s) are reported. 
Statistical significance was defined as p < 0.05 or 95% confidence intervals (CI) for OR 
not including 1.0. All statistical analyses were performed using the SPSS v 19.0 
statistical software. 
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Ethics:	  
The study complied with the Declaration of Helsinki. The BIO-HF database 
was approved by the Central Ethical Committee of the UZ Brussel and the Maria 
Middelares Hospital Gent.(2010/262). Informed consent was obtained from all 
patients or their legal representatives.  
RESULTS	  
A total of 977 patients were included in the BIO-HF registry between 
November 2006 and May 2012.  
	  
Atrial	  	  fibrillation	  complicating	  acute	  heart	  failure	  
Data regarding AF on admission were missing in 20 patients (6 women, 14 
men). AF occurred in 432 of the remaining 957 patients (45.1%); in 194 out of 429 
women and in 238 out of 528 men (45.2% vs. 45.1%, p=0.97). (Figure	  1)	  It was the first 
episode of AF in 31.5% of the women and 36.8% of the men (p=0.32) while AF was 
permanent in respectively 29.7% and 25.8% (p=0.42). In multivariable analysis, left 
atrial diameter was the single independent predictor for AF on admission; OR 
1.07/mm (95% CI 1.03-1.10), p<0.001.
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Baseline	  characteristics:	  
Baseline characteristics of all patients in the registry and those with AF (all 
and patients <75 years) are shown in	  Table	  1.	  	  
Demographics,	  risk	  factors	  and	  comorbidities	  
Compared with men, women were older and more likely to have a history of 
hypertension while smoking, COPD and a history of CAD were less prevalent 
among women. An ACS was the precipitating factor for HF in 7.1% of the women 
with AF vs. 9.3% of the men with AF (p=0.48). Histories of hyperlipidaemia, 
diabetes, PAD, stroke, dementia, malignancy and thyroid disease were not different 
between sexes.  
Clinical,	  biochemical	  and	  echocardiographic	  characteristics:	  
Mean heart rate was higher in women vs. men with HF (95.1 bpm vs. 91.5 
bpm, p=0.04) but comparable among women and men with AF complicating AHF 
(104.4 bpm vs. 100.5 bpm, p=0.21). Mean systolic blood pressure was not significantly 
different between sexes.   
There were no sex related differences in the presence of anaemia on admission 
but more women than men had RD on admission (all: 63.6 % vs. 54.4%, p=0.005, AF: 
67% vs. 56.2%, p= 0.03).  
Data on LVEF were available in 93% of the patients, the mean ejection fraction 
was higher in women vs. men and more women than men had HF-PEF. The presence 
of MR (> grade II) was not different between sexes. Medications from home recorded 
on admission were similar between female and male patients with AHF, except for 
aldosterone receptor antagonists in patients with AHF and AF (women: 22.7% vs. 
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Table	  1	   All	  BIO-­‐HF	  patients	   All	  BIO-­‐HF	  patients	  with	  AF	   All	  BIO-­‐HF	  patients	  with	  AF	  <75y	  
	   Women	  (N=435)	   Men	  (N=542)	   Women	  (N=194)	   Men	  (N=238)	   Women	  (N=40)	   Men	  (N=77)	  
Demographics,	  risk	  factors	  and	  comorbidities	  
Age	  (mean,	  SD)	   80.1	  (8.9)	   74.6	  (11.9)***	   80.6	  (7.5)	   77.3	  (10.1)***	   69.4	  (4.3)	   65.6	  (8.1)**	  
Age	  <75y	   21.6	   41.7***	   20.6	   32.4**	   _	   _	  
History	  of	  AF	   21.8	   19	   47.5	   40	   41.7	   32	  
Smoker	   5.1	   17***	   4.1	   13**	   10	   22.1	  
Hypertension	   67.1	   57.6**	   70.1	   59.7*	   75	   54.5*	  
Diabetes	   	   25.1	   28.4	   25.8	   25.6	   35	   26	  
Hyperlipidaemia	   43.8	   48.6	   41.8	   45.9	   30.6	   44	  
CAD	   25.1	   43.9***	   22.2	   42.4***	   15	   31.2	  
PAD	   14.9	   19.2	   15.5	   17.2	   10	   17	  
Stroke	   11.4	   11.7	   13.9	   13.4	   5	   3.9	  
Dementia	   4.8	   3.5	   6.2	   2.9	   2.5	   1.3	  
COPD	   15.9	   21.2*	   12.6	   24.9**	   8.3	   10.7	  
Malignancy	   12.1	   12.3	   14.4	   14.0	   6.9	   8.0	  
Thyroid	  disease	   19.6	   15.0	   20.8	   14.7	   12	   15.7	  
ACS	  	   14.9	   18.7	   7.1	   9.3	   8.3	   8	  
Clinical,	  biochemical	  and	  echocardiographic	  characteristics	  on	  admission	  
SBP	  (mean,	  SD)	   142.3	  (31.6)	   139.0	  (28.9)	   142.1	  (30.0)	   138.6	  (26.1)	   144.1	  (32.9)	   137.8	  (28.5)	  
HR	  (mean,	  SD)	   95.1	  (27.5)	   91.5	  (28.1)*	   104.4	  (30.8)	   100.5	  (33.2)	   114	  .6	  (30.6)	   115.6	  (35.1)	  
RD	   63.6	   54.4**	   67.0	   56.2*	   56.4	   36.8	  
Anaemia	  	   38.4	   41.8	   35.9	   37.4	   40.5	   25.5	  
LVEF	  (mean,SD)	   47.1	  (16.3)	   38.7(16.0)***	   48.1	  (16.0)	   40.8	  (16.2)***	   42.1	  (15.9)	   35.9	  (15.3)	  
HF-­‐PEF	  	   52.4	   30.3***	   53.9	   35.7***	   33.3	   27.8	  
MR>grade	  II	   20.7	   16.7	   19.6	   16.2	   11.1	   17.7	  
Treatment	  on	  admission	  
Β-­‐blocker	   54.5	   50.6	   61.3	   52.5	   67.5	   46.8	  
ACE-­‐I/ARB	   49.9	   54.2	   51	   51.7	   62.5	   45.5	  
ARA	   17	   14.9	   22.7	   14.3*	   25	   13	  
Loop	  diuretic	   46	   46.9	   46.7	   54.1	   41.7	   40	  
Digoxin	   10.7	   12.5	   10.7	   12.5	   11.1	   20	  
Sotalol	   4.6	   3.5	   6.8	   5.4	   2.8	   5.3	  
Amiodarone	   9.0	   13.9*	   9.6	   13.1	   8.3	   16.0	  
VKA	   22.3	   26.2	   40.7	   42.4	   45	   36.4	  
AF=	  atrial	  fibrillation,	  y=	  years,	  CAD=	  coronary	  artery	  disease,	  PAD:	  peripheral	  artery	  disease,	  COPD=	  chronic	  obstructive	  pulmonary	  disease,	  ACS=	  acute	  coronary	  
syndrome,	  SBP=	  systolic	  blood	  pressure,	  (mmHg),	  HR=	  heart	  rate	  (beats/minute),	  RD=	  renal	  dysfunction,	  LVEF=	  left	  ventricular	  ejection	  fraction,	  MR=	  mitral	  
regurgitation,	  ACE-­‐I=	  angiotensin	  converting	  enzyme	  inhibitor,	  ARB=	  angiotensin	  receptor	  blocker,	  ARA=	  aldosterone	  receptor	  antagonist,	  VKA=	  vitamin	  K	  
antagonist.	  Data	  are	  presented	  as	  %	  unless	  otherwise	  indicated,	  *p<0.05;	  **	  P<0.1;	  ***	  p<0.001	  
Female	  gender	  in	  acute	  cardiac	  care	   84	  
Treatment	  during	  and	  after	  hospitalisation	  
The general therapeutic approach of AHF and the specific treatment of AF 
was not different between men and women with AHF and AF; an equal amount of 
men and women were treated with intravenous diuretics (67.2% vs. 66.7%, p=0.92), 
intravenous nitrates (18.6% vs. 19.4%, p=0.89), inotropic therapy (2.8% vs. 6.3%, 
p=0.15), non invasive ventilation (2.3% vs. 3.2%, p=0.76) and electrical cardioversion 
(4.8% vs. 4.3%, p=0.81) A comparable proportion of women and men were 
prescribed amiodarone (28.2% vs. 31.1%, P=0.58), digoxin (29.4% vs. 29.7%, p=0.99) , 
β-blocker (73.7% vs. 76.1% , p=0.58) and sotalol at discharge (3.4% vs. 0.5%, p=0.05). 
More women than men were prescribed aldosterone receptor antagonists (36.1% vs. 
26.5%, p=0.04) at discharge. Overall 60% of the women vs. 63.4% of the men (p=0.49) 
were prescribed oral anticoagulants at discharge. (Table	  2) 
Subgroup	  <75	  years	  	  
In the subgroup of patients <75 years, 43% of the women had co-occurring AF 
vs. 35.2% of the men, p=0.20. The prevalence of AF in younger women was 
comparable to that in older women (p=0.64) while AF was less prevalent in the 
younger vs. the older men (35.2 vs. 52.1%, p<0.001). The women <75 years with AHF 
and AF were on average older and more frequently had a history of hypertension as 
compared to the men <75 years. Other sex differences, observed in the overall group 
of patients with HF and AF (smoking, CAD, COPD, renal dysfunction, HF-PEF and 
the use of an aldosterone receptor antagonist at discharge) did not reach statistical 
significance in this subgroup. Fewer women <75 years with HF and AF had HF-PEF 
as compared to women ≥75 years with AHF and AF (33.3% vs. 59.2%, p=0.008) 
whereas the proportion of male patients with HF-PEF was similar among men < and 
≥75 years (27.8 vs. 39.5%, p=0.10). No sex differences in the treatment of HF and/or 
AF were observed in this subgroup. Patients younger than 75 years more often 
underwent electrical cardioversion (p=0.03) for their AF during hospital stay and 
were prescribed more often ACE-I or ARB at discharge as compared to patients ≥75 
years (P=0.003). (Table	  2)  
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Table	  2	  	  	  	  	  	  	  	  In-­‐hospital	  treatment	  of	  patients	  with	  acute	  heart	  failure	  and	  atrial	  fibrillation	  
	   All	   AF<75years	  












IV	  nitrates	   18.6	   19.4	   0.89	   22.2	   21.3	   0.99	  
IV	  inotropics	   2.8	   6.3	   0.15	   5.6	   9.3	   0.71	  
IV	  diuretics	   67.2	   66.7	   0.92	   61.1	   73.3	   0.20	  
	  NIV	   2.3	   3.2	   0.76	   5.6	   2.7	   0.59	  
Electrical	  cardioversion	   4.8	   4.3	   0.81	   6.2	   9.6	   0.72	  
Β-­‐blocker	  at	  discharge	   73.7	   76.1	   0.58	   77.5	   83.1	   0.46	  
ACE-­‐I/ARB	  at	  discharge	   55.2	   62.6	   0.14	   67.5	   72.7	   0.67	  
ARA	  at	  discharge	   36.1	   26.5	   0.04	   27.5	   32.5	   0.67	  
Amiodarone	  at	  discharge	   28.2	   31.1	   0.58	   30.6	   37.3	   0.53	  
Digoxin	  at	  discharge	   29.4	   29.7	   0.99	   25	   37.3	   0.28	  
Sotalol	  at	  discharge	   3.4	   0.5	   0.05	   2.8	   1.3	   0.54	  
VKA	  at	  discharge	   59.8	   63.4	   0.49	   67.5	   64.9	   0.84	  
IV=	  intravenous,	  NIV=	  non	  invasive	  ventilation,	  ACE-­‐I=	  angiotensin	  converting	  enzyme	  inhibitor,	  ARB=	  angiotensin	  receptor	  blocker,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
ARA=	  aldosterone	  receptor	  antagonist,	  VKA=	  vitamin	  K	  antagonist,	  Data	  are	  presented	  as	  %	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Outcome	  
	   Data on the primary outcome were available in >95% of the patients (10 men 
and 12 women were lost to follow-up, Figure	  1). The composite of one-year all cause 
mortality or rehospitalisation occurred in 70 (out of 182, 38.5%) women and 82 (out 
of 228, 36%) men (p=0.93). When adjusting for sex, age, admission heart rate, 
hypertension, renal dysfunction, CAD, HF-REF, COPD, active smoking, β-blocker at 
discharge, VKA at discharge, ACE-I or ARB at discharge and aldosterone receptor 
antagonist at discharge, female sex was not independently associated with the 
primary endpoint (OR=1.1 [95% CI 0.65-1.86], p=0.71). Renal dysfunction (OR=2.88 
[95% CI 1.68-4.92], p<0.001) and β-blocker at discharge (OR=0.46 [95%CI 0.26-0.79], 
p=0.005) were independently associated with the outcome measure. (Table	  3) A 
significant interaction between sex and age was observed (p=0.002) with a doubling 
of the primary endpoint in women <75 years-of-age (42.5%) vs. men <75 years-of-age 
(20.3%); (OR=7.17 [95% CI 1.79-28.66], p=0.005). (Table	  4),	  (Figure	  2)	  
Restoration of sinus rhythm at discharge occurred in 16.5% of the women and 
in 14.2% of the men (p=0.58). In-hospital mortality rates were comparable between 
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Table	  3	  	   Multivariable	  analysis	  of	  the	  composite	  endpoint:	  	   	   	   	  
One-­‐year	  mortality/rehospitalisation	  in	  female	  (N=194)	  and	  male	  (N=238)	  
patients	  with	  atrial	  fibrillation	  complicating	  acute	  heart	  failure	  
	   p-­‐value	   OR	   95%	  CI	  
Gender	   0.71	   1.10	   0.65-­‐1.86	  
Age	   0.05	   1.03	   1.00-­‐1.07	  
Admission	  HR	   0.69	   0.99	   0.99-­‐1.01	  
Hypertension	   0.19	   1.41	   0.85-­‐2.36	  
Renal	  dysfunction	   <0.001	   2.88	   1.68-­‐4.92	  
COPD	   0.40	   1.31	   0.70-­‐2.42	  
Active	  smoking	   0.14	   1.92	   0.81-­‐4.53	  
CAD	   0.88	   1.05	   0.61-­‐1.79	  
LVEF	  <	  50%	   0.13	   1.48	   0.89-­‐2.46	  
Β-­‐blocker	  discharge	   0.005	   0.46	   0.26-­‐0.79	  
VKA	  discharge	   0.33	   0.77	   0.46-­‐1.29	  
ACE-­‐I/ARB	  discharge	   0.20	   0.72	   0.44-­‐1.19	  
ARA	  discharge	   0.07	   0.61	   0.35-­‐1.04	  
HR=	  heart	  rate,	  COPD=	  chronic	  obstructive	  pulmonary	  disease,	  CAD=	  coronary	  artery	  disease,	  LVEF=	  left	  ventricular	  ejection	  fraction,	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Table	  4	  	   Multivariable	  analysis	  of	  the	  composite	  endpoint:	  
1-­‐year	  mortality/rehospitalisation	  in	  female	  (N=40)	  en	  male	  (N=77)	  patients	  	  	  	  	  	  	  	  
<75	  years-­‐of-­‐age	  with	  atrial	  fibrillation	  complicating	  acute	  heart	  failure	  
	  
	   p-­‐value	   OR	   95%	  CI	  
Gender	   0.005	   7.17	   1.79-­‐28.66	  
Age	   0.83	   1.01	   0.91-­‐1.12	  
Admission	  HR	   0.38	   0.99	   0.97-­‐1.01	  
Hypertension	   0.64	   1.42	   0.32-­‐6.26	  
Renal	  dysfunction	   0.12	   3.01	   0.75-­‐12.01	  
COPD	   0.04	   10.18	   1.05-­‐98.51	  
Active	  smoking	   0.08	   4.51	   0.86-­‐23.76	  
CAD	   0.69	   0.76	   0.20-­‐2.91	  
LVEF	  <50%	   0.12	   2.95	   0.75-­‐11.67	  
Β-­‐blocker	  discharge	   0.43	   0.55	   0.13-­‐2.37	  
VKA	  discharge	   0.04	   0.24	   0.06-­‐0.94	  
ACE-­‐I/ARB	  discharge	   0.89	   1.10	   0.27-­‐4.46	  
ARA	  discharge	   0.15	   0.37	   0.09-­‐1.42	  
HR=	  heart	  rate,	  COPD=	  chronic	  obstructive	  pulmonary	  disease,	  CAD=	  coronary	  artery	  disease,	  LVEF=	  left	  ventricular	  ejectionfraction,	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Figure	  2	  	   Adjusted	  1-­‐year	  mortality	  and	  rehospitalisation	  
	  
	  
Dark	  grey	  bars:	  Women	  
Light	  grey	  bars:	  men	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DISCUSSION	  
This analysis, based on a large contemporary HF registry, conducted in 2 
Belgian centres, demonstrated that AF was present in 45% of the patients admitted 
for AHF and that AF was equally prevalent among women and men. Despite gender 
differences in risk profile and comorbidities, the incidences of outcomes (composite 
of one year mortality and/or rehospitalisation, restoration of sinus rhythm and in-
hospital mortality) were similar among these women and men presenting with AHF 
and AF. However a significant sex-age interaction was demonstrated and outcome in 
the group of women < 75 years-of-age was worse as compared with men <75 years. 
As far as we are aware this is the first report that demonstrates worse outcome in 
younger women hospitalised with AHF complicated by AF.  
The high prevalence of AF in hospitalised HF patients in this contemporary 
registry is consistent with the findings of McManus et al. that the incidence of co-
occurring AF is increasing in patients with AHF, in women as well as in men. 126 As in 
other AHF registries, the women in our registry differed from men in being older, 
more frequently having hypertension, more frequently having HF-PEF and less 
frequently having a history of CAD. 32, 33, 35, 107, 157 In contrast to previous reports 33 a higher 
incidence of renal dysfunction on admission was observed in women probably 
because renal function was assessed using eGFR (< or ≥ 60mL/min/1.73m2), instead 
of a cut-off value for creatinine, the latter being a less accurate way to determine 
kidney function especially when evaluating sex differences.163, 164 In the subgroup of 
patients <75 years no sex differences in comorbidities (except for hypertension) were 
observed, this could be attributed to the lower sample size. However, in contrast to 
the women ≥ 75years, less women <75years presented with HF-PEF.  
 We observed no sex disparities in the application of evidence-based HF 
therapies before and during admission and at discharge, with the exception for 
aldosterone receptor antagonists at discharge, which were prescribed more to 
women, despite the greater proportion of women with HF-PEF, who should not 
receive aldosterone receptor antagonists according to the current guidelines. The 
management of AF was similar between men and women with a predominant rate 
control strategy in both women and men, which may be a reflection from the lessons 
learned from the AF-CHF trial. 165 
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In the BEST-trial including 2,708 patients (22% women) relatively young 
(mean age 58y [SD 13.3] and 61y [SD 12.0] in women and men respectively) chronic 
HF patients with reduced ejection fraction, AF was an independent predictor for 
mortality in women but not in men. 166 In a setting of AHF, we demonstrated worse 
outcome for women <75 years with AF compared with men <75 years, however, our 
data do not provide a clear insight into the reason for this worse outcome, because 
sex differences in baseline characteristics and treatment were less pronounced in this 
group compared with the older age group. Women have a higher risk of mortality 
and morbidity from stroke and thromboembolism (TE) associated with AF. 161 Based 
on this finding (reflected by the CHA2DS2 VASc score) all women with AF and at least 
one additional risk factor (HF, age >65 , DM, history of stroke/TIA/TE, vascular 
disease) are at higher risk (CHA2DS2 VASc ≥2). 162 Treatment with VKA or novel 
anticoagulants can reduce this risk by two thirds.  This implies that all women, 
younger or older, admitted with HF and AF should be discharged with anticoagulant 
treatment. In the current database an equal amount of men and women were 
discharged on oral anticoagulants. Not prescribing VKA antagonists at discharge 
was associated with worse outcome in both sexes of the younger patient group, 
unfortunately reasons for not prescribing VKA were not recorded. Therefore the lack 
of VKA at discharge cannot explain the worse outcome in younger women but the 
results of the multivariable analysis stress the need for oral anticoagulation in all 
patients admitted with HF and AF. Women have longer QT-intervals than men and a 
treatment with sotalol makes them more susceptible for torsades de pointes 21, 167, 
however sotalol was prescribed only to a minority of these patients and adding 
sotalol to the multivariable model did not change the results in the age group <75 
years (OR for female sex=10.99 [95%CI 2.29 -52.81], p=0.003). The use of digoxin at 
discharge was high (more than 25% of the patients), post hoc analyses of the Digitalis 
Investigation Group (DIG) trial demonstrated that digoxin at higher serum 
concentrations (≥ 1.2ng/mL) was associated with a HR for death of 1.33 in women. 22, 
168 Unfortunately digoxin levels at discharge were not registered in the database. The 
addition of digoxin at discharge to the multivariable model did not affect the results 
in the age group<75 years either (OR for female sex=11.49 [95% CI 2.34-56.55], 
p=0.003).  
Before speculating on other reasons behind the worse outcome in younger 
women with AHF and AF, this finding should be explored in larger patient series.  
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STRENGHTS	  AND	  WEAKNESSES	  
The BIO-HF registry is a contemporary HF registry that provides accurate 
assessment of baseline characteristics and follow-up data, allowing adjustment for 
differences in aetiologies and comorbidities. There are some weaknesses: First, the 
nonrandomised and observational design of the BIO-HF registry is subject to 
residual and unmeasured confounding. Second, AF can present in many ways, the 
current analysis was not pre-defined, when setting up the BIO-HF registry and it was 
not recorded in the database when AF started, whether AF was the trigger for AHF 
or merely a marker of the severity of the disease. Third, the sample size of the 
subgroup analysis based on age < or ≥ 75y is limited and limitations of subgroup 
analysis are known. The large confidence intervals for the main outcome of interest 
in women <75 years may reflect lack of precision due to the smaller sample size in 
this subgroup of younger patients, therefore we consider our results hypothesis 
generating. 
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CONCLUSION	  AND	  IMPLICATIONS	  
The BIO-HF registry conducted in 2 Belgian hospitals demonstrated no sex 
differences in prevalence and treatment of AF in patients hospitalised with AHF. The 
composite endpoint of one-year mortality and rehospitalisation among patients with 
AHF and AF was not different between sexes, except for women <75 years-of-age 
who were at higher risk for adverse outcome compared with men <75 years. The 
worse outcome for younger women is worrying and the reason behind this could be 
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ABSTRACT	  
Introduction:	  Peripartum	  cardiomyopathy	  (PPCM)	  patients	  refractory	  to	  medical	  therapy	  and	  intra-­‐
aortic	  balloon	  pump	  (IABP)	  counterpulsation	  or	  in	  whom	  weaning	  from	  these	  therapies	  is	  impossible,	  
are	  candidates	  for	  a	  left	  ventricular	  assist	  device	  (LVAD)	  as	  a	  bridge	  to	  recovery	  or	  transplant.	  
Continuous-­‐flow	  LVADs	  are	  smaller,	  have	  a	  better	  long-­‐term	  durability	  and	  are	  associated	  with	  better	  
outcomes.	  Extra	  corporeal	  membrane	  oxygenation	  (ECMO)	  can	  be	  used	  as	  a	  temporary	  support	  in	  
patients	  with	  refractory	  cardiogenic	  shock.	  The	  aim	  of	  this	  study	  was	  to	  evaluate	  the	  efficacy	  and	  
safety	  of	  mechanical	  support	  in	  acute	  and	  critically	  ill	  PPCM	  patients.	  
Methods:	  This	  was	  a	  retrospective	  search	  of	  the	  patient	  database	  of	  the	  Ghent	  University	  
Hospital	  (2000-­‐2010).	  
Results:	  Six	  PPCM-­‐patients	  were	  treated	  with	  mechanical	  support.	  Three	  patients	  presented	  in	  the	  
postpartum	  period	  and	  three	  patients	  at	  the	  end	  of	  pregnancy.	  All	  were	  treated	  with	  IABP,	  the	  
duration	  of	  IABP	  support	  ranged	  from	  1	  to	  13	  days.	  An	  ECMO	  was	  inserted	  in	  one	  patient	  who	  
presented	  with	  cardiogenic	  shock,	  multiple	  organ	  dysfunction	  syndrome	  and	  a	  stillborn	  baby.	  Two	  
patients	  showed	  partial	  recovery	  and	  could	  be	  weaned	  off	  the	  IABP.	  Four	  patients	  were	  implanted	  
with	  a	  continuous-­‐flow	  LVAD	  (HeartMate	  II®,	  Thoratec	  Inc.),	  including	  the	  ECMO-­‐patient.	  Three	  LVAD	  
patients	  were	  successfully	  transplanted	  78,	  126	  and	  360	  days	  after	  LVAD	  implant,	  one	  patient	  is	  still	  
on	  the	  transplant	  waiting	  list.	  We	  observed	  one	  peripheral	  thrombotic	  complication	  due	  to	  IABP	  and	  
five	  early	  bleeding	  complications	  in	  three	  LVAD	  patients.	  One	  patient	  died	  suddenly	  2	  years	  after	  
transplantation.	  
Conclusions:	  In	  PPCM	  with	  refractory	  heart	  failure,	  IABP	  was	  safe	  and	  efficient	  as	  a	  bridge	  to	  
recovery	  or	  as	  a	  bridge	  to	  LVAD.	  ECMO	  provided	  temporary	  support	  as	  a	  bridge	  to	  LVAD	  while	  the	  
newer	  continuous-­‐flow	  LVADs	  offered	  a	  safe	  bridge	  to	  transplant.	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INTRODUCTION	  	  
Peripartum cardiomyopathy (PPCM) is a rare disease that affects women in 
the last month of their pregnancy or in the early puerpium (up to 5 months after 
delivery); it is characterised by left ventricular systolic dysfunction and symptoms of 
heart failure (HF) without any identifiable cause of HF. The incidence varies from 
1:15,000 to 1:1,300 deliveries in some African countries and 1:299 in Haiti and is 
thought to be lower in Europe. 169, 170 The historically bad prognosis with mortality rates 
ranging from 4 to 80% has improved because of advances in HF treatment. 171 
Although already described in the 19th century the condition was only 
defined as Peripartum Cardiomyopathy in 1971 by Demakis et al. who also proposed 
diagnostic criteria that later were confirmed during the ‘Peripartum 
Cardiomyopathy: National Heart Lung and Blood Institute and Office of Rare 
Disease Workshop’ in 2000. 172 Several aetiologies have been proposed comprising 
myocarditis, auto-immune mechanisms and pregnancy associated hormonal 
changes. 173-175 Recent data support the hypothesis that PPCM may develop as a result 
of complex interactions of pregnancy-associated factors against a susceptible genetic 
background. 176, 177 The oxidative stress-cathepsin D-16 kDa prolactin hypothesis has 
been raised as a possible common pathway on which different aetiologies that induce 
PPCM may merge. While newer therapies such as bromocriptine appear promising 
and will be tested in larger trials one must also concentrate on an optimal treatment 
strategy for the acute and critically ill PPCM patients, allowing to increase survival in 
this young patient population. 178 
Heart transplantation is an accepted treatment option for patients with 
refractory HF due to PPCM although a higher incidence of rejection has been 
reported in parous women, particularly in the first six months after transplantation. 
179, 180 Moreover, heart transplantation is limited by a lack of suitable donors. On the 
other hand there is a reasonable possibility of partial or complete recovery of left 
ventricular function, during the first year. The main predictors for recovery are an 
initial left ventricular end-diastolic dimension (LVEDD) <56mm and an ejection 
fraction >45% at two months. 171 As a consequence there is a need for appropriate 
temporary short- and long-term artificial support for the acute and critically ill 
patients. There are only a few reports on mechanical support devices as a bridge to 
recovery or transplantation in this setting. Data on the use of intra aortic balloon 
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pump (IABP) and extra corporeal membrane oxygenation (ECMO) in PPCM are 
scarce. 181-184 There are a few reports on the use of pulsatile assist devices in this setting, 
most of them as a bridge to transplant and in a minority of cases as bridge to 
recovery. 185-192 
Continuous-flow LVADs are a newer type of assist devices that have 
advantages over the older pulsatile devices: they are smaller, have a better long-term 
durability and their use is associated with improved survival and functional 
capacity. 193, 194 There are no published series on the use of a continuous-flow device in 
patients with PPCM. 
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MATERIALS	  AND	  METHODS	  
A retrospective 10-year study (2000-2010) was conducted of our patient 
database (department of Cardiology, Ghent University Hospital, Belgium) for 
patients with a need for mechanical support in the acute phase of PPCM. Mechanical 
support was defined as IABP, ECMO or LVAD. We received local Ethical Committee 
approval and informed consent from the patients or their relatives.  
Diagnosis of PPCM was based upon development of symptoms of HF due to 
systolic dysfunction in the last month of pregnancy or within five months after 
delivery without any identifiable cause of HF or recognisable heart disease prior to 
the last month of pregnancy. Patients with hypertensive HF in the peripartum period 
were not included. Demographic, clinical, hemodynamic and echocardiographic data 
as well as data on serology were evaluated. Data on endo-myocardial biopsies and 
coronary angiography were reviewed. The outcomes of the different treatment 
strategies as well as their complications were evaluated. 
	  
RESULTS	  
Over a 10-year period 6 PPCM patients were treated with mechanical support 
for acute HF at our center. (Table	  1) All six patients were treated with an IABP and 
one patient was treated with ECMO. Four patients were implanted with a 
continuous-flow LVAD (HeartMate II®, Thoratec Inc, Pleasanton, USA), three of 
them were transplanted and one patient is still on the transplant waiting list. The 
mean age at presentation was 34.7 years, the mean body surface area (BSA) was 
1.76m2 . Five patients were Caucasian, one was native African. All patients but one 
were multiparous with the number of pregnancies ranging from two to four. 
Serology was examined for Coxsackie virus B1-5, Mycoplasma pneumoniae, 
Toxoplasmosis, Hepatitis B and C, HIV, Ebstein-Barr and Adeno- and Entero virus in 
all patients. Active infection with Mycoplasma pneumoniae was found in 2 patients 
but active myocarditis was excluded by means of endo-myocardial biopsy. Endo-
myocardial biopsies in 2 other patients, taken at the time of placement of the LVAD, 
were also negative for myocarditis. 
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Table	  1	  	  	  	  	  	  	  	  Patient	  characteristics	  
Patient	   1	   2	   3	   4	   5	   6	  
Year	   2001	   2008	   2010	   2007	   2008	   2009	  
Age	  (y)	   34	   35	   36	   37	   38	   28	  
BSA	  (m2)	   1.90	   1.88	   1.58	   1.83	   1.60	   1.79	  
Race	   C	   A	   C	   C	   C	   C	  
Obstetrical	  Hx	   G4A0P4	   G2A0P2	   G4A0P4	   G1A0P0	   G2A0P1	   G3A1P1	  
Symptom	  onset	   3wPP	   5mPP	   5mPP	   38wPr	   35wPr	   38wPr	  
Diagnosis	   3wPP	   10mPP	   18mPP	   38wPr	   36wPr	   38wPr	  
Clinical	  picture	   APE	   ADHF	   ADHF	   ADHF	   ADHF	   CS	  
LVEDD	  (mm)	  	   55	   62	   79	   53	   61	   68	  
Serology	   Negative	   Mycoplasma	  IgM	   Negative	   Negative	   Negative	   Mycoplasma	  
IgM	  
Coronary	  angio	   Normal	   -­‐	   Normal	   -­‐	   Normal	   -­‐	  
Biopsy	   -­‐	   Negative	   Negative	   -­‐	   Negative	   Negative	  
IABP	  (d)	   7	   13	   5	   4	   6	   1	  
ECMO	  (d)	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   7	  
LVAD	  (d)	   -­‐	   126	   Since	  
26/04/2010	  
-­‐	   360	   78	  







-­‐	   -­‐	   Bleeding	  anast.	  
aorta	  
	  
Outcome	   Recovery	   Tx,	  SD	  	  535	  days	  
postTx	  
Alive,on	  Tx	  list	   Recovery	   Tx	   Tx	  
y=	  years,	  BSA=	  Body	  Surface	  Area,	  C=	  Caucasian,	  A=	  African,	  Hx=	  history,	  PP=	  Postpartum,	  Pr=	  Pregnancy,	  APE=	  Acute	  Pulmonary	  Edema,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
ADHF=	  Acute	  Decompensated	  Heart	  Failure,	  CS=	  Cardiogenic	  Shock,	  LVEDD=	  Left	  Ventricular	  End	  Diastolic	  Diameter	  at	  presentation,	  d=	  days,	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Perop.=	  peroperative,	  anast.=	  anastomosis,	  AFC=	  Arteria	  Femoralis	  Communis,	  Tx=	  cardiac	  transplantation,	  SD=	  Sudden	  Death	  
	  
Female	  gender	  in	  acute	  cardiac	  care	   101	  
Presentation	  in	  the	  postpartum	  period	  
Patient 1 was a 34-year-old patient (G4A0P4) who presented with acute 
pulmonary oedema 16 days after delivery of a healthy son. She was initially treated 
with intravenous diuretics and vasodilators, but her condition only stabilised after 
insertion of an IABP. After initiation of conventional HF therapy with ACE-
inhibitors, diuretics and low dose beta-blockers the patient was easily weaned off the 
IABP and discharged home 4 weeks after admission. She is still in follow-up and 
doing well under treatment with beta-blocking agents. 
Patient 2 was a 35-year-old South African woman (G2A0P2) who developed 
progressive dyspnoea from the fifth month postpartum. She came to the Emergency 
Room a few months later with a clinical picture of severe decompensated HF with 
lactate acidosis and liver failure. After initiation of inotropic therapy and IABP 
insertion her condition stabilised with complete resolution of the lactate acidosis and 
liver function. Despite initiation of proper HF therapy weaning off the IABP was not 
possible and the implantation of a LVAD was decided. The implantation was 
complicated by a rupture and large hematoma of the descending aorta for which an 
endo-prosthesis was inserted. During the early postoperative phase 2 revisions were 
necessary because of pericardial tamponade. Long-term antibiotic therapy was 
initiated because of infection of the pocket. After a long postoperative period the 
patient could be mobilised and discharged home 67 days after placement of the 
LVAD. No recovery in left ventricular function was noted during follow-up. A total 
of 126 days after implantation of the LVAD she was successfully transplanted and 
did well. Unfortunately she died suddenly 2 years later, she developed EMD during 
hospitalisation for HF due to mild rejection, prolonged resuscitation was 
unsuccessful. An autopsy was not performed. 
Patient 3, a 36-year-old mother of 4 children, presented very late in the 
postpartum period (18 months postpartum), she developed progressive symptoms of 
HF during the first months after her last delivery. She presented with cachexia and 
decompensated HF. The left ventricular end-diastolic diameter was 79 mm at 
presentation. After minor decongestion with diuretics, low dose dopamine was 
started and an IABP was inserted because of refractory hypotension and low output 
failure. Five days later an LVAD was implanted electively because of lack of left 
ventricular recovery and impossibility to wean the patient off the IABP and 
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dopamine. The postoperative course was complicated by a spontaneous rectus 
haematoma at the 11th postoperative day (supratherapeutic prothrombin time) and a 
thrombotic occlusion of the right common femoral artery. The arterial occlusion was 
a consequence of the IABP and a thrombectomy was performed at day 35 post LVAD 
with good clinical resolution afterwards. During ambulatory follow up, left 
ventricular end diastolic diameter decreased from 79 to 72 mm without recovery of 
left ventricular function. 
Presentation	  late	  in	  pregnancy	  
Two patients presented with acute decompensated HF and were in New York 
Heart Association class III. An IABP was inserted in both patients prior to caesarean 
section.  
Patient 4, a 37-year-old nulli-para could be weaned off the IABP four days 
later and is still under treatment with conventional HF therapy and is doing well. 
 Patient 5, a 38-year-old woman (G2A0P1) could be weaned off the IABP after 
six days but remained symptomatic the following weeks with severe hypotension 
necessitating a continuous dopamine infusion. She was treated with bromocriptine 
but remained inotrope-dependent. She was implanted with a LVAD 21 days after 
removal of the IABP. There were no complications. Follow-up echocardiography 
showed some recovery of left ventricular function but the right ventricular function 
remained moderate; a trial to remove the LVAD was not attempted. She was 
successfully transplanted almost one year after LVAD placement and is still doing 
well. 
The sixth patient, a 28-year-old G3A1P1 developed rapidly progressive 
dyspnea at the end of pregnancy. HF was initially not recognized and delivery was 
induced with prostaglandins. Afterwards she rapidly progressed to cardiogenic 
shock. She was referred to our center. During transport a continuous infusion with 
adrenaline was initiated because of severe shock. Upon arrival the patient was 
immediately intubated, meanwhile an IABP was percutaneously inserted. A stillborn 
baby was delivered by caesarean section. The patient remained in shock with severe 
lactate acidosis and multiple organ dysfunction syndrome despite treatment with 
dobutamine, levosimendan and high doses of noradrenaline. Her condition 
worsened rapidly, she was not stable enough for implantation of a LVAD. An ECMO 
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was percutaneously inserted at the bedside without complications. The system 
comprised a Medos Hilite 7000 LT oxygenator (Medos Medizintechnik AG, Stolber, 
Germany) and a Sorin revolution centrifugal pump (Sorin Group, Arvado, Colorado, 
USA)  (18 Fr arterial line: femoral approach, 18 Fr venous line: jugular approach). The 
following days we noted respiratory and metabolic improvement. Because of the 
absence of left ventricular recovery a LVAD was implanted after seven days of 
ECMO. There was a revision at day 1 because of bleeding at the anastomosis of the 
aortic cannula. During the postoperative course she was treated for ventilator 
associated pneumonia with complete recovery. Sildenafil treatment for moderate 
right ventricular function and pulmonary hypertension was initiated at the fourth 
day post-LVAD implantation until transplant. She was discharged home 37 days 
after initial admission and was successfully transplanted 78 days after LVAD 
implant and is doing well up till now 
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DISCUSSION	  
We describe six well-documented cases of severe PPCM that presented with 
AHF requiring mechanical support. The diagnosis was based upon development of 
symptoms of HF in the last month of pregnancy or during the first five months after 
delivery without arguments for pre-existing structural heart disease. In each patient 
an extensive work-up was performed to exclude other causes of HF. Two patients 
had arguments for active Mycoplasma Pneumoniae infection, but myocarditis was 
excluded by means of endo-myocardial biopsies.  
We describe short- and/or long-term mechanical support when intensive 
medical therapy fails to stabilise a PPCM patient with severe HF. Mechanical short-
term support can be provided percutaneous with IABP or ECMO. An IABP can 
easily be placed at the bedside and has little side effects in this young patient 
population. There are no randomised data on the use of IABP in non-ischaemic 
refractory HF and European guidelines recommend insertion of an IABP when 
inotropes fail to restore the blood pressure and signs of hypo-perfusion persist. 195 In 
our series the use of IABP up to 13 days was complicated by one thrombotic 
occlusion of the common right femoral artery which was corrected uneventfully after 
thrombectomy. All patients treated with IABP were anti-coagulated with 
unfractionated heparin (UFH) aiming at an activated partial thromboplastin time 
(aPTT) of 65-85 seconds. Weaning from the IABP is usually attempted over 1 to 3 
days by gradually decreasing the 1:1 support to a 1:2 and a 1:3 support. If a 1:3 
support is well tolerated for at least 4 hours, the IABP is removed. When weaning off 
the IABP is not possible, the IABP is removed at the time of implantation of the 
ECMO or the LVAD.  
There is a current trend to use short-term support with ECMO in refractory 
cardiogenic shock but data from large randomised trials are lacking. ECMO is 
considered as an emergency rescue therapy for patients with refractory cardiogenic 
shock; their condition is so unstable that they are not eligible for immediate LVAD 
implantation. The ECMO can be inserted at the bedside; it is relatively cheap (as 
compared to the implantable LVAD) and it gives the treating physicians some time 
to wait for recovery or a more stable condition. However close monitoring of the 
coagulation parameters is needed and it is therefore, labour-intensive. Patients on 
ECMO are treated with UFH in order to obtain an activated clotting time (ACT) of 
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170-200 seconds. Anti-thrombin III (ATIII) levels are analysed daily, ATIII 
concentrate is given if the ATIII activity drops below 70%. A visco-elastic coagulation 
measurement is checked twice daily or whenever bleeding occurs. Patients on 
arterio-venous ECMO are ventilated with conventional settings, with a FiO2 to 
achieve an acceptable PaO2 (at least 60 mmHg). Inotropic support is reduced and 
stopped but milrinone is often continued for its dilator properties and positive effects 
on microcirculation. Fluid management is aimed at preserving renal function and 
ensuring a stable circulation. As ECMO flow depends on right atrial filling, this is 
monitored by means of echocardiography. During a weaning attempt each partial 
decrease in ECMO flow should be compensated by an increase in stroke volume 
without excessive increase in inotropic support. There are 3 case reports on ECMO in 
PPCM where ECMO served as a safe bridge to recovery. 182, 184 In our series ECMO was 
used in one patient because of refractory cardiogenic shock and multiple organ 
dysfunction syndrome one-day post caesarean section. ECMO allowed 
haemodynamic and metabolic stabilisation. In contrast to the above mentioned case 
reports we saw no recovery of left ventricular function and in our patient ECMO 
served as a bridge to LVAD.  
LVADs offer a more long-term support. In a recent position statement Sliwa et 
al. promote the use of a mechanical assist device in PPCM in case of refractory HF 
despite optimal medical therapy. 96 The continuous-flow HeartMate II was introduced 
in 2004 and has shown improvement in survival, reduction in adverse events and 
improved functional capacity. 193 This axial flow pump draws the blood on a 
continuous basis from the left ventricle via an apical drainage cannula and propels it 
back into the aorta by a rotary pump in a non-phasic flow pattern. Its smaller size 
makes it suitable for patients with a low BSA, which is frequently the case in this 
young female population. After implantation of the LVAD NO-ventilation is 
routinely applied in our center to support the right ventricle, inotropic support is 
gradually decreased and replaced by oral HF therapy. Echocardiography is used to 
assess left ventricular filling, a neutral inter-ventricular septum position indicates 
adequate left ventricular filling. Bleeding complications in the immediate 
postoperative phase still pose a problem but recent data on the HeartMate IIe device 
support a less aggressive anticoagulation protocol. 186, 190 More recently late bleeding 
complications up to 44.3% have been observed in continuous-flow LVAD patients, 
possibly due to an acquired von Willebrand Syndrome. 196 In our center the 
antithrombotic regimen is started as soon as drain output reaches levels of 50 ml/h 
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or less. It comprises Aspirin 100mg and Enoxaparin 40mg once daily (20mg in case of 
GFR<30ml/minute, 60mg in case of body weight>90kg). Acenocoumarol (target INR 
1.5 to 2) is started as soon as a more stable hemodynamic condition is reached and in 
the absence of bleeding. Bleeding complications were observed in three patients 
during the early postoperative phase, with need for revision in two patients. We 
observed no late bleeding complications. Infection of the pocket with need for long-
term antibiotic treatment occurred in one patient. There were no thrombotic 
complications related to the LVAD, despite the fact that PPCM is a pro-thrombotic 
condition. Right heart failure, defined as the postoperative need for temporary right 
ventricular mechanical or inotropic support for more than 14 days following 
implantation, was not noted although one patient was treated until transplantation 
with a low dose Sildenafil. Neurological complications did not occur in this small 
series. Sufficient recovery of left ventricular function to allow LVAD explantation is 
rare but has been described in PPCM patients treated with pulsatile devices, we 
found no data on explantation of continuous-flow devices in PPCM patients. In our 
series we saw a decrease in LVEDD and some improvement in left ventricular 
function, but the right ventricular function remained moderate. In our opinion the 
decrease in LVEDD and improvement in left ventricular function can be attributed to 
the unloading of the left ventricle.  
These six patients presented over a wide time range between 2001 and 2010 
with a trend towards an increasing incidence over the last three years at our center, 
this stresses the need for a national and international registry for this pathology. One 
could argue that the therapy has become more invasive over the years; the first two 
patients being managed with IABP alone. However the more invasive therapy 
(ECMO, LVAD) in the patients who presented later is attributable to the more severe 
condition of these patients with the inability to wean the patients off IABP and/or 
intravenous inotropes. Despite the fact that bromocriptine appears promising as a 
novel disease-specific treatment, we initiated it briefly in one patient (patient 5) and 
stopped it after implantation of the LVAD. Currently it is not clear whether the 
results of the proof of concept study by Sliwa et al. where bromocriptine was added 
to standard HF therapy (ACE-inhibitors, aldactone, betablockers and diuretics), can 
be extrapolated to this patient population dependent of IV inotropes and/or 
mechanical support. We hope that future trials will address this question. 178 
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CONCLUSIONS	  
In acute and critically ill PPCM patients, mechanical support with IABP, even 
prior to delivery, is safe and feasible and serves as a bridge to partial recovery or as a 
bridge to LVAD. ECMO can serve as a bridge to LVAD, in case of refractory 
cardiogenic shock despite IABP and full inotropic support. The newer continuous-
flow assist devices are a safe bridge to transplant for PPCM patients who cannot be 
weaned off intravenous inotropic support or mechanical support with IABP or 
ECMO. The role of bromocriptine treatment in these patients needs to be explored in 
future trials. Based on the literature and our experience we propose an algorithm for 
the treatment of acute and critically PPCM.	  (Figure	  1)	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Key	  messages	  
• Acute and critically ill PPCM patients refractory to medical therapy should be 
treated with mechanical support. 
• IABP support is feasible and safe in the pre- and postpartum period as a bridge to 
recovery or as a bridge to assist device. 
• In patients with refractory cardiogenic shock and Multiple Organ Dysfunction 
Syndrome despite IABP, ECMO should be considered as a temporary ‘emergency 
rescue’ support (bridge to recovery or bridge to LVAD).  
• Continuous-flow LVADs are safe as a bridge to transplant in this young patient 
population. 
• Bromocriptine, a novel disease-specific treatment, can be considered in these 
patients. 
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V.	   Discussion	  
________________________________________________________	  
 
This thesis focuses on the clinical characteristics and outcomes of women with 
acute cardiac disease, more specifically STEMI and AHF, with specific attention for 
gender differences in outcome. In general one fourth of STEMI patients and half of 
AHF patients are comprised of women, which was also the case in the analysed 
STEMI- and HF- registries used in this work.  
We compared in-hospital mortality and the predictive performance of the 
TIMI risk score in STEMI between male and female patients undergoing pPCI 
(Chapter	  1) and we evaluated gender differences in the prevalence and prognostic 
impact (in-hospital mortality) of renal dysfunction in these patients (Chapter	  2). We 
studied gender differences in the prevalence, treatment and prognostic impact (in-
hospital mortality and 1-year rehospitalisation and mortality) of AF in AHF (Chapter	  
3). Furthermore the outcomes of STEMI-patients and AHF-patients with co-occurring 
AF were evaluated in two age groups, a younger and older age group (< and ≥ 65 
years in STEMI, < and ≥ 75 years in AHF) (Chapters	  1	  and	  3). Finally we evaluated the 
safety and efficacy of mechanical support in critically ill PPCM patients in Chapter	  4.  
In Chapter	  1 we evaluated 8,073 patients included in the Belgian STEMI registry 
(23.8% female patients) who underwent pPCI and we demonstrated that, after 
adjusting for the TIMI risk score variables, the risk of in-hospital mortality was 
higher in women (OR=1.47 (95% CI 1.15-1.87, p=0.002). After further adjustment for 
age a sustained mortality gap was demonstrated in the younger population of <65 
years-of-age (OR=1.73 [95% CI 1.07-2.82], p=0.03) but not in the population ≥ 65 years 
(OR=1.27 [95% CI 0.96-1.68], p=0.09). We further demonstrated that the TIMI risk 
score demonstrated a good prognostic discrimination in men and women but the 
mortality prediction for TIMI risk score was slightly better in men (p=0.02 for TIMI 
score x gender interaction).  
Worse short-term outcome in younger women, suffering an ACS, was reported 
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earlier, however these older reports often included NSTEMI and STEMI patients and 
women were less likely than men to undergo a coronary intervention. 65 Other reports 
investigating short-term outcomes in men and women undergoing pPCI for STEMI 
were conflicting but the sample sizes were often small with exception of the paper by 
Benamer, including 16,760 STEMI patients of whom 82.6% of the male and 88.9% of 
the female patients were treated with pPCI, demonstrating a comparable in-hospital 
mortality difference between genders (10.1 % in women vs. 4.9% in men compared to 
our registry: 9.8% in women vs. 4.3% in men). 113 In contrast to our findings, this 
mortality difference remained only significant in patients >75 years-of-age after 
multivariable adjustment. This can be due to the fact that other and more clinical 
variables (history of hypertension, history of CAD, tachycardia, hypotension, 
ischaemic time>4h, low body weight, infarct localization) for adjustment were used 
in our analysis. A worse 30-day outcome for younger women <50 years as compared 
to men was also observed in a large real-world Italian population treated with PCI. 197 
Just recently, the worse short-term (30-day) outcome in women <65 years treated 
with pPCI for STEMI was confirmed by a single centre study from the Netherlands, 
including the exact same amount of women <65 years (N=708). 198 
Why is female gender associated with mortality in this young patient population? 
In our analysis this could not be explained by the higher prevalence of hypertension 
or diabetes, nor by the lower bodyweight, the worse clinical profile (higher Killip 
class, more tachycardia and hypotension) nor the higher prevalence of ischaemic 
times >4 hours. Longer ischaemic times, defined as ischaemic times >4h were not 
related to mortality in our analysis but it remains unclear to what extent the worse 
clinical profile in women could be improved by reducing ischaemic times and what 
impact this would have on gender differences in outcome. Furthermore the use of 
ischaemic time as a dichotomous variable instead of a continuous variable and the 
cut-off of 4h can have influenced our results since mortality already increases at door 
to balloon times of > 90 minutes (irrespective of symptom onset time) and even 
shorter in high risk patients. 199 The longer ischaemic times may partly be related to 
the fact that more women than men present without chest pain, a sex difference that 
is even larger among younger women, however this lack of chest pain among 
younger women was not associated with increased mortality after adjustment. 25 A 
lack of awareness, both at the patient and at the physician level may also result in 
different access to care and longer time delays between symptoms and diagnosis 
followed by therapy. 200 Longer ischaemic times seem to be associated more with long-
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term outcomes. 201 Reducing time delays is therefore one of the most important 
modifiable factors that might have an influence on outcome.  We did not have data 
on severity of coronary artery disease but in the analysis by Otten et al. the younger 
women had less pronounced coronary artery disease (more single vessel disease and 
more TIMI 3 flow) at the moment of presentation as compared to the men while their 
outcome was worse. Data on smoking, the use of oral contraceptives or hormone 
replacement therapies were not available either in the registry but these are mere risk 
factors for the development of acute coronary syndromes and long-term outcome 
rather than risk factors for an adverse short-term outcome. 202 Women are also known 
to have a higher complication rate (especially vascular and bleeding complications, 
dissection, abrupt closure due to the smaller vessel size) 84, 85, 203 which was not recorded 
in our registry and not adjusted for. Despite the fact that women have been shown to 
have greater myocardial salvage with pPCI compared to men 92 they seem to be at 
higher risk for HF complicating MI 94, 204. The higher risk for this HF complicating MI 
has been attributed to sex differences in remodelling (less ventricular dilatation) 
which may be protective in the long run but can lead to increased incidence of HF on 
the short-term. In our registry more women presented with cardiogenic shock, which 
was adjusted for, however we did not have information on the development of HF 
during hospitalisation for MI. We did not explore differences in use of evidence 
based therapies in women, some reports indicate that the prescription of evidence 
based therapies in the acute phase post-ACS is not different between women and 
men while others reported that these therapies were less often prescribed to women 
at discharge. 81, 198, 203 There is no information on gender differences in the short-term 
effects of these medications but their effectiveness on the long term was investigated 
demonstrating that the benefit of the combination of a of beta-blocker with a statin 
and the combination of a beta-blocker with an ACE-I or ARB was significantly 
greater in men than in women. 23  
Finally it is possible that other unknown confounders or an unidentified 
biological or non-biological factor might explain the gender-difference in in hospital-
mortality among younger women suffering STEMI .   
Despite the gender differences in outcome after adjustment for TIMI risk 
variables, the TIMI risk score for STEMI provided a good prognostic performance in 
both genders, indicating that the relative contribution of age, comorbidities and a 
worse clinical profile seems to be weighted well by this score confirming its value for 
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early risk stratification at the bedside in men as well as in women. The mortality risk 
prediction of the TIMI risk score was slightly better in men and interaction tests 
demonstrated a larger impact of admission tachycardia, admission hypotension and 
Killip class > I in men.  
In Chapter	  2 we demonstrated in a subgroup (N=1,638) of patients included in the 
Belgian STEMI registry that, despite their lower levels of serum creatinine, more 
women than men suffered renal dysfunction (eGFR<60mL/min/1.73m2) at the 
moment of hospital admission for STEMI. Renal dysfunction was associated with in-
hospital mortality, independently of the TIMI risk score and gender. The interaction 
test demonstrated that this impact was comparable for men and women. Renal 
dysfunction, assessed by eGFR, could therefore be an important reason why women 
with STEMI die more than men and should be taken into account when evaluating 
gender differences. Our data do not reveal why female gender is associated with 
renal dysfunction nor why renal dysfunction is associated with worse outcome. 
Again we suppose that there are unknown confounders or an unidentified sex-
specific factor that could explain the higher incidence of renal dysfunction among 
women with STEMI. Renal dysfunction is associated with complications of which 
acute kidney injury and bleeding are the most likely to occur, both associated with 
short-term mortality. 147, 205 Furthermore renal dysfunction may serve as a surrogate 
marker for general health and for unknown risk factors that influence outcome. 
Routine calculation of eGFR on admission allows to identify high-risk patients and to 
initiate preventive strategies for contrast-induced nephropathy and bleeding.  
In Chapter	  3 we demonstrated that there were no gender differences in the 
prevalence and treatment of AF in patients hospitalised for AHF and that the 
composite end-point of 1-year mortality and re-hospitalisation was not different 
between sexes. However further subgroup analysis of patients < and ≥ 75 years 
revealed an adjusted worse outcome for women <75 years-of-age as compared to 
men <75 years-of-age with a significant sex-age interaction. AF on admission was 
present in 45% of the patients in the BIO-HF registry and this finding is in line with 
recent findings that the incidence of co-occurring AF in HF-patients is increasing. 126 
Women differed from men in being older, more frequently having hypertension, 
more frequently having HF-PEF and less frequently having a history of CAD as in 
other registries. 33 Our data do not provide clear insight into the reason behind the 
worse outcome in the younger patient group, in fact these younger women were 
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more similar to the younger men in terms of baseline characteristics than the older 
women to the older men but this can be due to the lower sample size. Most 
importantly HF-PEF was less prevalent among the younger women than the older 
women. This suggests that when a woman becomes more equal to a man in terms of 
ejection fraction, her prognosis gets worse. Ghali et al. found in a group of relatively 
young HF patients that AF was an independent predictor for mortality in women but 
not in men but this was not yet demonstrated in the setting of AHF. 166 It is known 
that women with AF have a higher risk of mortality from stroke and 
thromboembolism especially when they have additional risk factors such as HF. 162 
However ‘not prescribing VKA’ at discharge was adjusted for and did not change 
our results. We also adjusted for the use of Sotalol and Digoxin in these patients 
because their use is associated with worse outcome in women but this didn’t change 
our findings either.  21, 22 Before speculating on other reasons for the worse outcome in 
younger women with HF and AF this finding should be explored in larger patients 
series.  
In Chapter	  4 we evaluated the feasibility and safety of mechanical support in 
critically ill PPCM patients. First of all the need for mechanical support underscores 
the severity of the disease in this young population. Thanks to contemporary HF 
therapy the survival of these women has improved but in the acute phase mechanical 
support can be necessary as a temporary measure.  
The last 2 decades more disease specific therapies have been proposed, of which 
bromocriptine seems the most promising. 178, 206 In 2007 it was demonstrated in mice 
that the development of PPCM was mediated by enhanced oxidative stress and the 
subsequent cleavage of prolactin into an anti-angiogenic and pro-apoptotic 16-k-Da 
form. A new concept was born for the treatment of PPCM: inhibition of prolactin 
release with bromocripitine. 175 In 2010 a proof of concept study was published 
demonstrating a larger degree of left ventricular recovery in the 10 patients treated 
with bromocriptine on top of standard HF therapy as compared to 10 conventionally 
treated patients. 178 While larger multicentre and randomised trials are needed to 
confirm the benefit of bromocriptine in PPCM patients, a prospective multi-centre 
registry in Germany supported the potential benefit of bromocriptine on top of 
standard HF treatment but pointed out that it may not be sufficiently effective in all 
patients, especially those with a very low ejection fraction (<25%). 
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 As in the United States the use of mechanical support for PPCM also increased in 
our centre the last decade. 207 Improvement, or even better, recovery of left ventricular 
function is possible but less likely to occur when the left ventricle is severely dilated, 
as illustrated in this case series. 171 The two women with a LVEDD <56 mm showed 
recovery after respectively 4 and 7 days of uncomplicated support with IABP and 
initiation of proper HF therapy. The other 4 patients with a LVEDD ranging from 61 
to 79 mm could not be weaned off the IABP (N=3) or ECMO (N=1) and were 
implanted with a continuous-flow assist device, which was safe as a bridge to 
transplant. Early bleeding complications were observed in three of these patients, 
there were no late bleeding complications. Despite the fact that PPCM is a pro-
thrombotic condition we observed no thrombotic complications in the LVAD 
patients.  Infection of the pocket occurred in one patient. A recently published larger 
patient’s series demonstrated that PPCM patients who receive durable mechanical 
support have a better survival compared to women who receive it for non-PPCM. 
This is mostly related to the fact that these patients are younger and have less 
comorbidity at presentation. 98 This stresses the fact that this therapy should not be 
withheld in PPCM patients with refractory HF. Based on our findings we propose an 
algorithm for the treatment of acute and critically PPCM patients. In general, this is 
not so different from the algorithms for the treatment of acute HF. The initiation of 
conventional oral HF therapy during pregnancy remains challenging; ACE-I, ARB 
and aldosterone antagonists are contra-indicated; oral hydralazine with or without 
long-acting nitrates can serve as an alternative but this is not supported by evidence. 
5, 96 	  
Limitations	  of	  this	  work:	  	  
The use of nonrandomised registries has several drawbacks. First, as in all 
registries one of the limitations are missing data. There were no missing data in 
chapter	  1 since a patient file could only be finalised when all required data were 
provided. For the sub-analysis on renal dysfunction in chapter	  2, the eGFR could not 
be calculated in 11.9% of the cases, due to missing creatinine values while in the 
dataset used in chapter	  3 data on LVEF were missing in 6.9% of the cases. Second, the 
data were examined using risk adjustment models; however, we cannot exclude 
other confounding factors as mentioned above that were not registered in the 
databases. Third, the characterisation of some continuous characteristics into 
dichotomies (e.g. body weight, ischaemic times) was inherent to the registries and 
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may have introduced residual confounding and hence biased our results to some 
extent. Fourth, although the registries require enrolment of all consecutive patients at 
participating centres, selection biases cannot be excluded. Finally, the possibility of 
inaccuracies in data coding or entry cannot be totally ruled out; for the STEMI 
database yearly audits, conducted by an external commission, of 10% of all patient 
files was performed to verify the validity of the data; the evaluation of these files 
demonstrated a 96% concordance rate between source documents and case report 
forms.  
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Final	  post	  hoc	  hypothesis	  
The background of the worse adjusted (traditional risk factors, treatment 
delay, clinical presentation) outcome in young female STEMI-patients is probably 
multi-factorial with biological (e.g. renal dysfunction) and non-biological factors (e.g. 
psychosocial factors) interacting in a complex and currently unravelled way. 
Younger women may need a higher burden of traditional risk factors to overrule the 
presumed protective effect of oestrogen, which could lead to a higher incidence of 
reno-vascular disease and hence renal dysfunction predisposing to adverse outcome. 
Furthermore non-biological factors such as social class (often associated with 
unhealthy lifestyle) and psychological factors such as anxiety, depression 208 and 
mental stress 209 are more prevalent among younger women with STEMI and may also 
negatively affect outcome. At higher ages, when the potentially protective effects of 
pre-menopause have disappeared gender differences in outcome may be explained 
by co-morbidities, clinical characteristics and the higher age these women are 
presenting with. Claiming that the same factors are responsible for worse outcome in 
young women with HF and AF would be too speculative since this finding was 
based on a sub-group analysis in a small sample.  
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VI	   Future	  perspectives	  
________________________________________________________	  
 
Further efforts are necessary to reduce the ‘gender gap’ in STEMI at younger 
age. In order to reach this goal more research is needed into the reasons behind the 
sex-differences in pathophysiology, clinical presentation, management and outcome. 
Dedicated registries, including all consecutive patients, could reveal to what extent 
biological and non-biological factors are responsible for this difference in outcome.  
In this era of the ‘interventionalisation’ of cardiology the main goal must 
remain to deliver optimal care to the individual patient, male or female, in a timely 
fashion. This starts with optimal tools for the selection of patients to undergo these 
interventions. Today it is not clear if sex-specific tools for history taking and 
interpretation of the ECG or different cut-offs for the interpretation of lab results, 
especially biomarkers, could be of any help. Meanwhile the suspicion for ACS 
should remain high in every patient with chest pain or common non-chest pain 
symptoms, also in the thirty- forty- and fifty-something woman coping with stress, 
especially those with cardiac risk factors such as diabetes, hypertension and 
smoking.   
Specific attention must go to the prevention of complications of interventional 
cardiology such as bleeding and contrast-induced nephropathy, two entities 
occurring more in women and associated with significant morbidity and mortality. 210 
Routine estimation of the GFR could be helpful for the selection of patients at risk 
and the initiation of preventive measures. Whether adding eGFR instead of serum 
creatinine could improve the prognostic performance of currently used bedside risk 
stratification models, especially in women, remains to be elucidated.  
Women are underrepresented in clinical trials, especially in the field of HF 
indicating that more women should be included in these trials in order to provide 
evidence based information to the physicians caring for these patients. Furthermore 
clinical trials investigating new pharmacological and non-pharmacological agents or 
techniques should pre-specify and report sex-specific outcomes, which is already 
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increasingly seen in recent literature. 211, 212 However the inclusion of patients in clinical 
trials can be subject of selection bias and one must take into account the 
shortcomings of subgroup analysis.  
Another on-going challenge is the timely diagnosis and the treatment of 
PPCM. Despite its low prevalence it is one of the main reasons for LVAD 
implantation in young women. Again the clinical suspicion for PPCM must be high 
in patients complaining of important dyspnoea in the peripartum period. 
Echocardiography and BNP are two tools that are easily accessible in the Western 
world that are very useful in this context because of their high negative predictive 
value. 96 Today it is not clear whether explanation of the LVAD is a safe option in 
patients demonstrating recovery of left ventricular function and what criteria should 
be used. Apart from the supportive treatment of HF, bromocriptine could be a 
disease specific treatment but data from a large randomised trial are lacking. 178 There 
might be another disease specific therapy emerging; unpublished data (oral 
communication, Mebazaa, 4th congress on Acute Cardiac Care, June 2014 Brussels) 
show lower levels of relaxin in women with PPCM. Serelaxin is a recombinant form 
of human relaxin-2, a naturally occurring peptide hormone that mediates the 
physiological cardiovascular and renal adaptations of pregnancy. 213 In the RELAX-
AHF trial IV infusion of Serelaxin to patients with AHF was associated with 
reduction of cardiovascular and all cause mortality at 180 days. 214 A clinical trial 
investigating the effect of IV Serelaxin in women with PPCM would therefore be of 
great interest.  
 Last but not least the awareness of female specific and nonspecific CVD must 
improve among the public and the health care workers in order to reach better 
outcome in women.  
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This thesis focuses on the clinical characteristics and outcome of women with 
acute cardiac disease. These were evaluated in the setting of STEMI and AHF. We 
compared mortality rate in STEMI between men and women and we evaluated 
gender differences in the prevalence and impact on prognosis of selected clinical 
variables more specifically renal dysfunction in the setting of STEMI and AF in the 
setting of AHF. In patients with PPCM we evaluated the efficacy and safety of 
different forms of mechanical support.  
 We demonstrated that mortality in female patients undergoing pPCI for 
STEMI is doubled vs. that in men. This is largely explained by the different clinical 
profile these women present with: they are older, have more comorbidities, present 
later and in a worse condition than their male counterparts. The TIMI risk score 
incorporates this clinical profile in a weighted fashion and provided a good 
prognostic discrimination and calibration with regard to the in-hospital outcome, 
however the prognostic impact of the TIMI risk score was slightly better in men. 
Adjustment for TIMI risk score variables and age demonstrated a significant gender 
difference in outcome in the population <65 years-of-age but not in the population 
≥65 years-of-age. The worse outcome in younger women was confirmed in other 
registries but the reason behind it remains unclear and could be investigated in 
future trials. 
  Renal dysfunction could be an important reason why women with STEMI 
undergoing pPCI die more than men: female gender was independently associated 
with renal dysfunction (defined as an eGFR <60mL/min/1.73m2) at admission and 
renal dysfunction had an equal prognostic impact on in-hospital outcome in men and 
women on top of the TIMI risk score. Therefore we advise early assessment of the 
renal function by calculation of eGFR in order to identify high-risk patients and to 
initiate preventive measures. 215 
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We observed no gender differences in the prevalence, the management and 
the prognostic impact on in-hospital and 1-year outcome of AF in patients with AHF. 
However a significant sex-age interaction was observed with worse outcome for 
women <75 years-of-age with AHF and AF compared to men <75 years-of-age with 
AHF and AF, a new finding that we consider hypothesis generating.  
Finally we evaluated the efficacy and safety of mechanical support in critically 
ill PPCM patients. While the small sample size reflects the rare character of this 
disease, the need for mechanical support on top of supportive medical therapy 
reflects the severity of this disease, affecting young women during pregnancy or in 
the early puerpium. IABP was safe and efficient as a bridge to recovery and safe as a 
bridge to LVAD. In one patient with refractory cardiogenic shock ECMO provided a 
feasible and safe bridge to LVAD. Four patients were implanted with a continuous-
flow LVAD (HeartMate II®, Thoratec Inc.) that offered a safe bridge to transplant. 
Based on our experience we propose a treatment algorithm for the treatment of acute 
and critically ill PPCM.  
One of the striking findings of this thesis is the poor prognosis for younger 
women presenting with acute cardiac disease while worse outcome in older women 
is largely explained by their co-morbidities, the worse clinical profile they present 
with and their higher age. More research is needed to explore the reasons behind the 
worse outcome in pPCI treated STEMI patients <65 years-of-age and AHF patients 
with AF <75 years-of-age.  
On-going efforts are needed to increase awareness for cardiac disease among 
women and their treating physicians in order to minimize delays to diagnosis and 
treatment in ACS as well as AHF.  
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Samenvatting:	  
In deze doctoraatsthesis ligt de nadruk op de klinische kenmerken en 
prognose van vrouwen met acute cardiale ziekte. Deze werden geëvalueerd in de 
setting van het ST- segment elevatie myocardinfarct (STEMI) en acuut hartfalen 
(AHF). We vergeleken de in-hospitaal mortaliteit tussen mannen en vrouwen bij 
STEMI. We onderzochten geslachtsverschillen in prevalentie en impact op prognose 
van geselecteerde klinische variabelen, meerbepaald nierfalen in de setting van 
STEMI en atriale fibrillatie (AF) in de setting van acuut hartfalen (AHF). Daarnaast 
evalueerden we de doeltreffendheid en veiligheid van verschillende vormen van 
mechanische cardiale ondersteuning bij patiëntes met peripartum cardiomyopathie.  
We toonden aan dat vrouwen die een behandeling met pPCI ondergingen in 
het kader van een STEMI eens zoveel kans hadden op overlijden in het ziekenhuis 
als mannen. Dit kon grotendeels maar niet volledig verklaard worden door het 
slechter klinisch profiel waarmee deze dames zich aanboden: ze waren ouder, 
hadden meer comorbiditeit en kwamen later en in slechtere klinische toestand naar 
de spoedopname.  De TIMI risico score houdt rekening met dit slechtere profiel op 
een gewogen wijze en bood in onze analyse een goede prognostische discriminatie 
en calibratie wat betreft in-hospitaal uitkomst van deze mannen en vrouwen; het 
prognostisch impact van deze score was echter iets beter bij mannen. Een 
multivariable regressie analyse die rekening hield met elk van de TIMI risk score 
variabelen en leeftijd toonde een significant slechtere uitkomst voor vrouwen <65 
jaar maar niet voor vrouwen ≥65 jaar.  Deze slechtere uitkomst voor jongere vrouwen 
werd aangetoond in andere recente en minder recente registers en de reden 
hierachter blijft tot op heden onduidelijk; dit zou een onderzoeksonderwerp kunnen 
zijn voor toekomstig onderzoek.  
Nierinsufficiëntie bij opname zou een belangrijke reden kunnen zijn voor de 
hogere in-hospitaal mortaliteit na STEMI bij vrouwen: nierlijden (gedefineerd als een 
eGFR <60mL/min/1.73m2 ) kwam meer voor bij vrouwen en ging gepaard met meer 
kans op in-hospitaal overlijden, onafhankelijk van de TIMI risico score. Daarom 
raden we aan om in de klinische praktijk de nierfunctie te bepalen op basis van de 
eGFR en aan te wenden om hoog risico patiënten te selecteren bij wie preventieve 
maatregelen kunnen worden genomen zoals bijvoorbeeld preventie van contrast 
geïnduceerde nefropathie.  
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We toonden aan dat er geen geslachtsverschillen zijn in de prevalentie, de 
behandeling en het prognostisch impact van AF bij patiënten met AHF. We toonden 
wel een interactie aan tussen geslacht en leeftijd met een slechtere uitkomst voor 
vrouwen <75 jaar met AHF en AF vergeleken met mannen <75 jaar met AHF en AF. 
Dit is een nieuwe bevinding in een kleine groep patiënten die we daarom als 
hypothese genererend beschouwen.  
Tot slot evalueerden we de doeltreffendheid en de veiligheid van mechanische 
ondersteuning bij patiëntes die kritisch ziek waren ten gevolge van peripartum 
cardiomypathie. De kleine patiëntengroep illustreert het zeldzame karakter van deze 
aandoening terwijl de nood aan mechanische ondersteuning aantoont hoe ernstig 
deze aandoening is. Een intra-aortische ballonpomp was veilig en efficiënt als een 
brug naar herstel of brug naar linker ventrikel assist device (LVAD). In één patiënte 
met refractaire cardiogene shock was een extra-corporele membraan oxygenator 
veilig als brug naar LVAD. Vier patiëntes kregen een LVAD (HeartMate II® , 
Thoratec Inc.) met continue flow als veilige brug naar harttransplantatie. Op basis 
van onze bevindingen stelden we een algoritme op voor de behandeling van PPCM.  
Eén van de belangrijke bevindingen van deze thesis is de slechtere prognose 
voor jongere vrouwen die zich presenteren met acute cardiale ziekte terwijl de 
minder goede uitkomst bij oudere vrouwen voornamelijk verklaard wordt door hun 
leeftijd, comorbiditeit en hun slechtere klinische profiel bij opname. Meer onderzoek 
is nodig naar de redenen voor de slechtere prognose bij vrouwen met STEMI <65 jaar 
en vrouwen met AHF en AF <75 jaar.  
Blijvende inspanningen zijn nodig om de bewustwording van cardiale ziekte 
te verbeteren bij vrouwen en artsen die deze vrouwen behandelen. Dit zou kunnen 
leiden tot een snellere diagnostiek en behandeling zowel bij acute coronaire 
syndromen als bij acuut hartfalen.  
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Key	  findings	  of	  the	  thesis:	  
• In-­‐hospital	  mortality	  is	  higher	  in	  female	  patients	  undergoing	  pPCI	  for	  STEMI,	  this	  is	  
largely	  explained	  by	  a	  worse	  clinical	  profile	  upon	  admission,	  as	  reflected	  by	  their	  
higher	  TIMI	  risk	  score	  for	  STEMI,	  as	  well	  as	  their	  higher	  age.	   
• Female	  STEMI	  patients	  <65	  years	  undergoing	  pPCI	  for	  STEMI	  remain	  at	  risk	  with	  a	  
higher	  adjusted	  in-­‐hospital	  mortality	  rate	  as	  compared	  to	  their	  male	  counterparts	  
(OR=1.73). 
• The	  TIMI	  risk	  score	  for	  STEMI	  is	  a	  reliable	  and	  simple	  bedside	  score	  suitable	  for	  early	  
risk	  stratification	  in	  women	  as	  well	  as	  in	  men	  undergoing	  ppCI	  for	  STEMI. 
• Renal	  dysfunction	  is	  more	  prevalent	  among	  women	  with	  STEMI	  and	  is	  associated	  with	  
in-­‐hospital	  mortality	  in	  both	  genders.	  	   
• There	  are	  no	  gender	  differences	  in	  the	  prevalence	  and	  treatment	  of	  AF	  in	  patients	  
hospitalised	  with	  AHF	  and	  the	  composite	  of	  1-­‐year	  mortality	  or	  rehospitalisation	  is	  
not	  different	  between	  men	  and	  women.	   
• Female	  patients	  hospitalised	  with	  AHF	  and	  AF	  <75	  years-­‐of-­‐age	  are	  at	  higher	  risk	  for	  
the	  composite	  of	  1-­‐year	  death	  or	  rehospitalisation	  compared	  to	  male	  patients	  <75	  
year-­‐of-­‐age.	   
• Mechanical	  support	  in	  critically	  ill	  PPCM	  is	  safe	  and	  efficient	  as	  a	  bridge	  to	  recovery	  
(IABP),	  as	  a	  bridge	  to	  LVAD	  (IABP,	  ECMO)	  and	  as	  a	  bridge	  to	  heart	  transplant	  (LVAD).
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